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ABSTRACT
The prevalence of diabetes is approaching epidemic proportions worldwide.
There is curently no cure for type 1 diabetes , and successful treatment requires constant
monitoring of blood sugars and use of exogenous insulin to prevent hyperglycemia.
Diabetes wil be curable when pancreatic islet cells can be transplanted into diabetes
patients without requiring long-term immunosuppression. This wil require learning more
about the induction of functional tolerance, a state that maintains the competence of the
immune system to most antigens but protects graft-specific antigens from immune
rejection, permitting transplantation. One known mechanism of peripheral tolerance is T
cell anergy, a phenotye ofhypo-reponsiveness in CD4+ T cells. The focus of this thesis
is a description of factors shown to be specific to the induction and maintenance of T cell
anergy, whose loss reverses the anergic phenotype, restoring the ability of the cells to
proliferate in response to antigen. The first of these is Egr- , a zinc-finger transcription
factor, whose presence is required for the induction of anergy induced in T cell clones by
TCR stimulation in the absence of co stimulation. Egr-2 is shown to be important to
anergy induction but not anergy maintenance. In contrast, a negative costimulation
receptor, PD- , is shown to be necessary for the maintenance of anergy. It is possible
that learning more about the genetic factors that orchestrate T cell anergy wil prove
useful in the development of tolerance-based protocols for organ and tissue
transplantation without the use of long-term immunosuppression.
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- Chapter 1 -
Diabetes Melltus, Transplantation, and Immunological Tolerance
Impact of Diabetes
The prevalence of diabetes melltus is approaching epidemic proportions. As of
2002, an estimated 18.2 milion people in the United States suffered from diabetes , with
one-third of them yet undiagnosed (1). Over the next fifty years, the number of diabetes
cases in the United States is expected to at least double (2), with recent trends seeing an
increase of 800 000 to 1.3 milion new diagnoses each year. Diabetes is the fifth leading
cause of death by disease in the United States (3). The rise seen in diabetes cases is not
limited to the United States: estimates from the International Diabetes Federation report
that 194 milion people worldwide currently suffer from diabetes , a significant increase
from the 1995 estimate of 134 milion. There is currently no cure for diabetes, only the
means to actively treat it. The high cost to patients ' personal lives from this disease and
the imperfect nature of available treatments wil make a cure for diabetes a welcome
emergence.
Description of Type 1 Diabetes
Diabetes melltus is a group of disorders having in common the pathologic
elevation of blood sugar levels (4). Although the lines distinguishing what have come to
be known as type 1 and type 2 diabetes are blurring of late, a distinction can stil be made
with regard to the cause of hyperglycemia. This classification was first proposed in the
mid- 1930s by Himsworth (5). Type 1 diabetes (until recently referred to as juvenile-onset
diabetes) is marked by the destruction of the ~ cells of the pancreatic islet, most
frequently due to autoimmunity. Approximately 5- 10% of total diabetes cases fit into
this category (6). In contrast, type 2 diabetes manifests as a relative insuffciency of
insulin rather than an absolute insuffciency, due to the inability of peripheral tissues such
as adipose tissue and skeletal muscle to make use of circulating sugars.
The real danger of type 1 diabetes is the damage it causes over the long term.
Chronic high glucose levels can be toxic, causing loss of vision, kidney failure, and heart
disease , and may lead to suffcient peripheral tissue damage to require amputation (4). A
new diagnosis of diabetes also mandates some significant lifestyle changes including
frequent insulin injections , constant monitoring of blood sugars , and careful attention to
diet and activity. These things together more than justify the large body of research
currently under way aiming to cure diabetes.
Etiology of Type 1 Diabetes
Most often, the root cause of type 1 diabetes is an autoimmune destruction of the
insulin-producing cells in the pancreas, the ~-islet cells (Figure 1). This has come to be
known as type lA diabetes , distinguishing it from those cases in which the cause of islet
destruction is undetermined, type 1 B. Why the immune system chooses to recognize the
pancreas as foreign and attack it is a complicated question, and many studies are

Legend for Figure 1
The progression of diabetes is visible histologically. A. A normal pancreatic islet
from a BioBreeder Diabetes-Prone rat B. Low levels of cellular infitration mark the
beginning of autoimmune islet destruction C. Complete functional destruction of the
islet: a high degree of cellular infitration and an almost complete loss of islet architecture
are visible. Images courtesy of Aldo Rossini.
under way seeking an answer to why autoimmune responses take place. It is well
accepted that many branches of the immune system arepathologically activated during an
autoimmune attack; for example, a major pre-diabetic finding is the presence of anti-islet
autoantibodies (7), suggesting the inappropriate activation of B cells. This is not the sole
immune lesion in type 1 diabetes, and in a percentage of diabetic patients anti-islet
antibodies are not even detectable (8). Studies have also implicated other compartments
of the immune system including numerous subsets of T cells, natural kiler cells
macrophages, and dendritic cells as being involved in the pathogenesis of diabetes (9
10). In humans, autoimmune diabetes is often associated with other autoimmune
disorders such as thyroiditis , celiac disease, Addison s disease, and pernicious anemia
(11), illustrating the scope and degree to which the immune system has missed its mark.
One arm of diabetes research aims to identify the factors responsible for triggering this
autoimmunity, and discover ways to prevent its onset.
Possible Triggers of Diabetes
The factors that trigger diabetic autoimmunity are not yet known, though there are
many hypotheses. A number of dietary factors have been implicated in diabetes
including cow s milk (12), meat (13), and wheat and barley proteins (14), but none of
these are widely accepted as stand-alone causes. Likewise, a number of viral infections
have been implicated as triggers for autoimmune diabetes (15- 17). In addition to the
environmental factors thought to playa role in causing diabetes, there is almost surely a
genetic predisposition to diabetes as well, complicating the story even further (18).
Discovering the environmental and genetic factors that trigger diabetes wil
provide areas of potential therapeutic intervention, eventually resulting in the means to
identify and protect predisposed individuals from developing diabetes. It 
unquestionable that research aimed toward preventing diabetes wil be invaluable to
current and future generations , but at the moment it is equally important that we discover
how to cure existing cases of diabetes given the large number of people whose lives
diabetes currently impacts. The costs of this disease are by no means limited to the
financial burden on both diabetic individuals and the general public. More importantly, a
diabetic s quality of life is significantly decreased in both the short term and long term
because of the disease s numerous sequelae.
Complications of Diabetes
When islet ~-cell destruction advances to such a degree that less than twenty
percent of a patient' s ~-cell mass remains , the remaining mass can no longer successfully
manage blood sugar levels and post-prandial hyperglycemia becomes a risk. The early
symptomatic manifestations of this can be frequent urination, excessive thirst, waking up
to urinate, incontinence, and weight loss (6). For the most part, these can be brought
under control by the administration of exogenous insulin. From this point on, managing
diabetes is a constant tightrope walk of monitoring sugars, estimating the carbohydrate
contents of meals, and administering enough insulin to prevent hyperglycemia without
using too much insulin, which can result in dangerously low blood sugar levels and loss
of consciousness.
Chronic hyperglycemia has debilitating long term effects, ultimately leading to
the early mortality seen in type 1 diabetes (4). Hyperglycemia can affect most organ
systems and lead to blindness due to retinopathy, kidney failure secondary to
nephropathy, and a multitude of peripheral nervous system problems. These include loss
of sensation of many types, loss of muscle strength, muscle wasting, decreased gut
motility, decreased bladder function, and postual hypotension. In addition to these
problems, known collectively as microangiopathies, diabetes is associated with
hyperlipoproteinemia, which is thought to cause coronary, cerebral, and peripheral
macrovascular disease. These can lead to heart attacks, strokes, and soft tissue ulcers
requiring amputation.
Current Therapies for Type 1 Diabetes
Insulin therapy remains the indispensable tool for controlling blood sugar in
patients with diabetes. First shown to decrease blood glucose levels in 1921 by Banting
and Best (Figure 2) it is remarkable to see how little diabetes care has actually changed in
concept since then (19). The basic strategy is mostly the same now as it was almost
ninety years ago: provide suffcient exogenous insulin to restore normoglycemia.
Specific insulin technologies have certainly improved, with the advent of many different
formulations of insulin whose pharmacokinetics differ (20), and dramatic improvements
have been made in home blood glucose monitoring, enabling the patient to achieve better
precision during self-administration of insulin (21). A recent attempt at achieving even
greater accuracy in insulin administration is the development of the insulin pump (22),
Figure 2
Legend for Figure 2
Experiments in 1921 by Banting and Best discovered the presence of a substance
(for which they coined the name "isletin ) in the pancreas that, when extracted, could
regulate the blood sugar of a diabetic dog.
which is worn at all times with a direct subcutaneous infusion set supplying insulin at a
consistent rate. The pump can be preset to deliver insulin at a specific basal rate with
bolus administrations at set times to compensate for carbohydrate intake at meals. 
significant advance wil be the development of a real-time blood glucose monitoring
system, which would give the patient the opportunity for great precision in insulin
administration and significantly reduce the chance of exceeding normal levels of blood
glucose. Just as importantly, it would reduce the risk of administering too much insulin
and suffering the effects of low blood sugar (23). The dangers of hypoglycemia are
mostly acute, as opposed to the more chronic damage caused by hyperglycemia.
Symptoms can include hunger, shakiness, and weakness accompanied by peripheral
vasoconstriction. In severe and prolonged instances, the brain can be deprived of glucose
so that a patient's condition can progress from diffculty in thinking and fatigue to loss of
integrative function, obtundation, and without proper treatment, coma. Most
hypoglycemic episodes can be remedied by ingesting some form of sugar.
Despite the importance of the recent advances in insulin technology, they only
make diabetes care more convenient. It is important to keep in mind that they do not
relieve a diabetic patient of the constant burden of blood glucose management.
The Goal: IS-cell Transplantation
Even if future technologies enable diabetes patients to manage their blood sugar
to increasingly precise degrees , they wil never come close to the precision and balance
achieved by the normal functioning of a non-diabetic pancreas. Thus, even better than
developing new technologies and training patients to better manage their sugar levels
would be to relieve them of the burden altogether. This wil be achievable when
medicine is able to introduce fully functional ~-islet cells into a patient's system where
they can monitor glucose levels and deliver insulin as if they were the patient's own cells.
The means for this are becoming a medical reality, thanks to the intensive studies
currently under way aiming to describe novel transplantation protocols. Replacing a
diabetic patient' s ~-islet cells with a pancreas or islet graft wil cure diabetes, but the
transplantation protocols that currently exist have enough of a negative impact on quality
of life that they are mostly reserved for life-threatening situations. The discovery of more
benign methods of transplantation than those currently used wil make curing diabetes a
reality.
Transplantation: An Overview
European mythology has passed down a legend from the third century in which
two physicians, the brothers Cosmas and Damien, remove a cancerous leg from a
European man and replace it with that of a Moor (24). Whether this tale was born of fact
or folklore, history offers Sts. Cosmas and Damien as the fathers of allo-transplantation.
The potential therapeutic uses for transplantation are extensive, but the barriers that
prevent their realization are largely the same mechanisms we depend on to protect us
from pathogens: the ability of the immune system to recognize and destroy anything it
perceives to be other than ourselves. This conundrum has become a primary hurdle in
successful allograft transplantation, especially since many of the anatomic technical
hurdles have been cleared. The first major breakthrough in the field took place in 1954
when Merril, Murray, and Harrison performed the first kidney transplant, using identical
twins as donor and recipient (25). This was truly a landmark event in medicine, opening
the gates for clinical opportities whose potential is stil being extended. Patients
survive surgery and trauma because of the ability to type and match blood for
transfusions, their vision is restored by cornea transplants, and the organs most
fundamental to our lives, the heart and lungs, can now be grafted as well (26).
The initial success of Merril, Murray, and Harrison can be partially attributed to
the identical genetic makeup of the donor and recipient. Transplanting tissues and organs
between genotypically mismatched individuals raises a myriad of problems , most of them
involving the activation of the normal immune response. The goal of modern
transplantation science is to learn to overcome these barriers to transplantation by means
that are of diminishing har to the recipient of a graft.
To date, transplantation medicine has protected grafted tissue from the host
immune system (and the host from the immune cells in the graft) by long-term
administration of immunosuppressive agents. For the most part, these regimens are
necessary to stave off immune rejection for the remainder of the patient' s life. The
evolution of immunosuppression has progressed from the use of cortisone and other
corti co steroids (27) to the most up-to-date agents such as mycophenolate mofetil and
sirolimus (28). Although new agents are selected in part because of their increasingly
benign side-effects profies , the consequences of long term systemic immunosuppression
remain: the burden of complying with a lifetime of numerous medications, increased
vulnerability to infectious organisms (29), and an increased risk of neoplasia (30). A far
preferable alternative to globally suppressing the immune systetn in order to allow the
introduction of a limited set of antigens would be to tailor or train the immune system to
allow only graft-specific antigens, while maintaining the competence to reject anything
else deemed foreign. Ideally, this treatment would preserve a graft recipient's ability to
fend off the majority of commonly encountered pathogens while hosting a fully
functional graft. The ultimate goal of transplantation research is to make it possible for a
fully functional organ to be transplanted into an immune-competent host to survive in the
absence of ongoing immunosuppression. Many studies toward this goal are underway,
and it is conceivable that medicine is less than a generation away from its realization.
Before this is a reality, however, there is much to be learned about how a normal immune
system works, and how it interacts with its surounding environment.
This goal of transplantation without immunosuppression has led researchers to
envision a physiological state called transplantation tolerance. The induction of a state of
functional tolerance would specify to a graft recipient's immune system which antigens
to permit but would leave the immune system competent to defend the recipient against
the multitude of pathogens it was designed to protect against. The processes by which a
host immune system rej ects a graft are not yet fully elucidated, and they are surely
immensely complex. This complexity provides many possible points of modulation at
which a rejection response could be dampened.
Pancreas/Islet Transplantation
The potential of replenishing a patient' s islet cell mass to cure diabetes was
conceived as far back as 1966, when the earliest pancreas transplantations were
performed (31). Until the advent of less harmful immunosuppressive agents such as
cyclosporine and anti- cell agents, however, pancreatic transplantation was not
common. Since the late seventies, the number of pancreatic transplants has increased
every year, with higher success rates and fewer complications overall (32). Many
different surgical techniques and immunosuppressive regimens have been used and
replaced by newer technologies , but transplantation medicine has yet to graduate from the
use of immunosuppression altogether (33). Transplantation of pancreatic tissue
specifically has additional drawbacks since some immunosuppressive agents have a
negative impact on ~ cell function (34). Due to the side effects profies of
immunosuppressive agents and the grim reality that patient compliance is a far cry from
one hundred percent (35), attempts to mitigate the impact of diabetes by transplantation
are currently reserved for cases with the most diffcult glycemic control.
In order to make less stringent the criteria justifying a pancreas or islet cell
transplant, it wil be necessary to understand the nature of functional tolerance, and
determine the means by which it may be possible to circumvent the immune system
natural defense mechanisms in order to persuade the body not to reject an allograft.
Developing a greater understanding of how the immune system permits some antigens
and disallows others may provide pathways to this end. Some progress has been made in
recent years. For example several diabetes patients have become insulin-independent
since receiving islet grafts facilitated by the Edmonton protocol. In these cases, steroids
were not used, and newer immunosuppressive drugs such as tacrolimus, rapamycin, and
anti-interleukin-2 receptor antibody were administered (36). With this breakthrough of
the development of a repeatable protocol in which patients achieved insulin-
independence, interest in islet transplantation is stronger than ever, bringing closer the
reality of a true cure for diabetes (37).
Before it wil be possible to harness the potential of functional tolerance to
achieve immunosuppression-free transplantation, it wil be necessary to learn more about
what tolerance actually is, and by what means we might be able to control it. Systemic
tolerance can be conceptually divided into central and peripheral tolerance. The induction
and control of either has great therapeutic potential and it may be possible to modulate
the nature of both in order to facilitate graft tolerance.
Central Tolerance
During normal T lymphocyte development, lymphocyte precursors emerge from
the bone marrow as pluripotent stem cells, and undergo numerous stages of maturation
after entering the thymus. The architecture of the thymus is intended to represent the
library of antigens potentially found in the body, and is an effective training ground for T
cells destined for the periphery. As T cell receptors are generated randomly in order to
achieve optimal antigenic diversity, it is possible for cells to express receptors
corresponding to self-antigens. The release of these T cells into the circulation could
prompt an immune response against healthy tissue. Thus one role of the thymus is to
educate the developing T cell repertoire as to the normal composition of the periphery
and thereby define the outstanding set of antigens as non-self. When a T cell whose
receptor corresponds to a self-antigen enters the thymus, it is deleted from the T cell
repertoire to prevent its contribution to an autoimmune attack. This process is known as
negative selection. Likewise, T cells whose receptors do not recognize antigens
expressed in the thymus proceed to express normal CD4 or CD8 receptors and are
permitted to exit the thymus and circulate in the periphery. This is termed positive
selection.
It is primarily this process of T cell selection in the thymus that is exploited
during the induction of central tolerance. By transplanting a graft donor s bone marrow
into a graft recipient, a state of hematopoietic chimerism can be achieved, specifically
altering the cellular environment of the recipient's thymus (38). At the point when a
donor-specific T cell enters the thymus it is interpreted as self-specific due to the
presence of graft-donor progenitor cells in the thymus, and is negatively selected. This
depletes the emerging population of T cells of graft-specific as well as self-specific
clones , creating an immunologically benign environment for the introduction of an organ
graft (39).
The process of negative selection is by no means perfect. A high percentage of
lymphocytes that undergo positive selection fall prey to a subsequent round of negative
selection (40). It is also well accepted that self-reactive T cells escape the thymus and are
able to circulate in plain view of their cognate antigens (41). In pathological instances
this results in a situation of autoimmunity in which the self is inappropriately attacked.
Luckily, this is not normally the case, as a safety net of mechanisms exists to maintain a
non-inflammatory environment despite the presence of circulating self-reactive cells (42).
These processes comprise peripheral tolerance.
Peripheral Tolerance
Despite decades of study, the processes that keep the immune system in check
outside the thymus have not been fully described, nor have their respective relevance
been assigned. There are numerous peripheral tolerance mechanisms that
, most likely in
combination, keep self-reactive cells in the periphery from developing into a pathological
autoimmunity . One proposed mechanism of peripheral tolerance is termed
immunological ignorance, a state in which immune cells circulate in the proximity of
their cognate antigens, but for an unkown reason are not compelled to respond to their
presence. This has been experimentally modeled by Ohashi, who showed an absence of
cytolytic activity in LCMV 
-specific lymphocytes circulating in proximity to LCMV-
epitope-expressing ~-islet cells (43). When the mice in this study were infected with
active LCMV, the lymphocytes became activated to confront and clear the infection
, and
incidentally attacked the epitope-expressing beta cells. It was only after the LCMV
infection that these mice developed diabetes due to the cytolytic activity of the LCMV-
specific memory population of T cells. Prior to infection, the virus-specific lymphocytes
circulated in a state of ignorance, possibly kept inactive because of an absence of
costimulation in the vicinity of the beta cells. This ignorance was broken when live virus
was introduced into the system, and the beta cells became casualties of the normal virus
clearing response.
Another proposed mechanism of tolerance in the periphery is extrathymic clonal
deletion, in which a population of lymphocytes specific to a given range of antigens is
directed into apoptosis in order to preserve the cells on which their cognate antigens
reside (44). This mechanism is usually most prevalent when high doses of antigen are
present (45). At lower doses , the emergence of cells that produce IL- , IL- , and TGF-
~ is a more prevalent phenomenon, skewing the immune system toward a Th2 response.
This skewing results in decreased IL-2 production by T cells and decreased T cell
proliferation (46). These effects come under the umbrella term of immune deviation
which encapsulates these processes and others.
Suppression of T cell responses has received a great deal of attention recently,
with most of the focus on the CD4+CD2S+ regulatory T cells first described by Sakaguchi
(47). These have been shown to prevent T cell responses in a contact-dependent manner
possibly orchestrated in some way by the transcription factor FoxP3 (48, 49) and the cell
surface protein GITR (50). The presence of these and other types of regulatory cells is
crucial to peripheral tolerance, as their absence results in the emergence of autoimmunity.
Another peripheral tolerance mechanism is T cell anergy, a state in which T cells
are actively rendered unresponsive to their cognate antigens (51). This form of peripheral
tolerance is the topic of this thesis and wil be discussed at length in later sections.
Briefly, clonal anergy is a phenotype resulting from the sub-optimal activation of T cells
which renders them umesponsive to antigenic stimulation. It is possible that peripheral
tolerance could be maintained over the long term by the rendering of specific clones of T
cells anergic rather than facilitating their activation. In order to discuss anergy, it is
useful to first describe the biochemical events that take place when a T cell is
productively stimulated.
T Cell Activation
The anergic phenotye is best understood against the backdrop of T cell
stimulation. During a normal immune response, CD4+ T cells are activated and have
numerous responsibilities, such as activating B cells, providing IL-2 help for CD8+ T
cells and producing interferon gamma (IFN-y) to activate macrophages and dendritic
cells. To prevent unsolicited T cell activity, T cells require two distinct signals through
receptors on the cell surface (52). One of these receptors , called the T cell receptor, is
unique to each T cell, and as a whole, the T cell repertoire is capable of recognizing and
reacting to an incredible diversity of antigenic patterns. The other signal can be delivered
through any of a number of receptors common to all T cells , generically known as
co stimulatory receptors. The most common of these is CD28. The sum effect of a T cell
receiving these two signals is the production of IL- , the primary growth cytokine for T
cells (Figure 3). The IL-2 produced is secreted by the cell concurrently with the up-
regulation of the IL-2 receptor, at which point IL-2 acts as an autocrine factor to drive
clonal expansion. The biochemical mechanisms ofIL-2 production are complex and the

Legend for Figure 3
T cells require two signals for activation. The sum effect of a signal through the
T cell receptor and a signal through a costimulatory receptor is a transduction cascade
resulting in the production ofIL- , a primar T cell growth cytokine. IL-2 is secreted
from the cell and acts as an autocrine factor, signaling via the T cell' s own IL-2 receptor.
The result of this is cell-cycle progression and clonal expansion.
subject of intense scrutiny. Upon receipt of a signal through the TCR from an MHC II
molecule presenting its cognate peptide, along with a costimulatory signal from a B7
family member, there is a wave of protein tyrosine kinase (PTK) activity that commences
T cell receptor signaling (53). The result of this activity is the initiation of downstream
signaling pathways including the mitogen activated protein (MAP) kinase pathway, an
influx of calcium, and the nuclear factor (NF) KB pathway. The sum of the contributions
from these three major T cell signaling pathways determines whether the outcome is a
stimulating or an ineffective signal.
Following TCR engagement, Src kinases Lck and Fyn are dephosphorylated by
CD45 family members (54). Now activated, these kinases are available to activate ZAP-
70 and Tec kinase family members (55), which can then activate immunoreceptor
tyrosine-based activation motifs (ITAMs) found in the cytoplasmic subunits of the TCR
complex (56). These phosphorylation events are subject to constant regulation by protein
phosphatases, and only when this regulation is held at bay by formation of the immune
synapse can successful TCR signaling occur.
One of the downstream consequences of PTK activation, as mentioned
previously, is an influx of calcium into the cell cytoplasm. The signaling cascade leading
to this biochemical event is initiated by the activation of phospholipase-Cyl (PLC-yl),
which cleaves membrane phosphatidyl inositol- 5 biphosphate (PIP ) into diacylglycerol
(DAG) and inositol- l,4, trisphosphate (IP ) (57). An increase in cytoplasmic IP
concentration releases Ca2+ from endoplasmic reticulum stores, followed by the opening
of surface membrane Ca2+-channels permitting additional Ca2+ influx from the
extracellular space (58). sustained increase in intracellular calcium activates
calcineurin, a phosphatase capable of targeting the Nuclear Factor of Activated T cells
(NFAT) (59). NFAT dephosphorylation exposes a nuclear localization signal, which
permits its passage across the nuclear membrane, at which point it can drive gene
transcription including that of the IL-2 gene.
The other by-product of PLC-yl activation, diacylglycerol, activates a number of
signaling molecules including various isoforms of protein kinase C (PKC) (58). One
result of PKC activation is the activation of p2l ras, which requires the exchange of GTP
for GDP to be activated. Ras activation triggers a cascade of kinase phosphorylation
events resulting in activation of the MAP kinases ERK, JNK, and p38 (58). In various
combinations , these activated factors migrate to the nucleus and up regulate jun and fos
transcription factors, which return to the nucleus and form a heterodimer named
Activating Protein- l (AP- l). AP- l binds to numerous sites in the IL-2 promoter, either
alone or complexed with NFAT, and is required for the up-regulation ofIL-2 (60).
A third transduction pathway crucial to T cell activation is the NFKB pathway. It
has been proposed that CD28 plays a crucial role in NFKB signaling, via the activation of
PI- kinase acting in synergy with PKC (58). NFKB is permitted to cross the nuclear
membrane upon ubiquitination of its inhibitory binding partner, IKB. NFKB , like NFAT
and AP- , contributes to T cell activation in part by binding the IL-2 promoter region and
driving transcription of IL-2. Some of the major elements of the T cell activation signal
transduction pathways are diagrammed in Figure 4.
Figure 4
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Legend for Figure 4
T cell signaling is a complicated network of signal transduction cascades. IL-
production requires input from at least three major signaling pathways: NFAT, the MAP
kinase pathway, and NFKB. Each of these involves many intermediate steps that are
subject to numerous regulatory mechanisms.
Costimulation
For a time, it was thought that the presence or absence of a signal through the
prototypic costimulatory receptor CD28 was the primary determinant of the outcome of a
tolerizing or immunizing stimulus. In the early nineties, the protein product of a gene on
the same chromosomal band as CD28 was found to bind B7 family members with a
greater affnity than CD28 (61). This protein, CTLA- , was found to inhibit T cell
responses, and its discovery ushered in the possibility that the decision between
activation and inhibition when a T cell is stimulated depends on some balance of signals
modulated by both the lymphocyte and the antigen presenting cell. Since these studies
were conducted, a number of other costimulatory and coinhibitory receptors have been
found. The mechanisms by which these groups of signaling proteins act are quite diverse
(62). Although the mechanisms are stil under investigation, a number of interesting
characteristics of these pathways are known. CD28 and CTLA-4 bind the same receptors
B7. l and B7.2 (CD80 and CD86, respectively), although it has been shown that CTLA-
can exert inhibitory effects independently of these (63). Other costimulatory and
coinhibitory receptors have unique ligands although most are members of the B7 family,
which has grown significantly in the past decade (62). Another T cell costimulatory
receptor is ICOS , which binds to ICOS Ligand in order to activate T cells. Unlike CD28
ICOS does not signal to NFKB or up-regulate CD40 (64), but it does stimulate PI3K
activity to a greater extent than CD28 (65). This apparent lack of redundancy ilustrates
the complex interplay of signals involved in costimulation, the full extent of which is
continuing to emerge. Other than CTLA- , one of the most well studied co inhibitory
receptors is PD- l. Originally discovered in apoptosis models (66), PD- l has garnered
much more attention for its inhibitory effect on T cell signaling. The mechanisms of PD-
1 inhibition have been the subject of many studies since its discovery, which wil 
discussed at length in later sections of this dissertation.
Since it was discovered that two signals are required for full T cell activation
studies have attempted to describe the individual contributions of the TCR and the
costimulatory receptor to IL-2 production. These studies have revealed that both
transcriptional and post-transcriptional regulatory mechanisms are most likely iJ? place to
control the amount of IL-2 being produced. Studies in human T cell blasts have
demonstrated that CD28 ligation by B7 family members in the absence ofTCR triggering
results in AP- l and NFKB activation, but not NFAT translocation (67). These activation
events were not suffcient to produce IL-2 suggesting that these signals serve mostly to
complement signals delivered by the TCR. CD28 ligation on resting T cells effected no
change in these studies. These findings were confirmed by a group examining the effect
of individual TCR and CD28 receptor engagement, who showed that very little JNK is
activated when these are stimulated individually, whereas it is strongly activated in the
presence of both signals , suggesting a synergism rather than an additive relationship
between the two (68). The importance of JNK as a possible point of cross-talk between
the TCR and CD28 signals has been confirmed by studies showing that its activity is
necessary for activation of disparate elements on the IL-2 promoter region, primarily the
AP- l binding sites and the composite CD28REI AP- l site. This implicates JNK in the
NFKB pathway as well as the AP- l pathway via the MAP kinases (69).
In addition to the regulatory mechanisms in control of IL-2 transcription, there is
evidence that there are post-transcriptional factors that determine levels of IL-2 protein
production. Studies examining the effect of co stimulation on IL-2 production have
shown that the half- life of IL-2 mRA is prolonged in the presence of costimulation
compared with cells stimulated through the TCR only (70). It is likely that this
prolongation is due to the blockade of destabilizing elements located in the 3' UTR
region of the mRNA by CD28 receptor engagement, although the mechanism of this has
not been shown. It has been proposed that the ability to produce IL-2 conferred by CD28
signaling is in large part due to the ability of CD28-derived signals to stabilize IL-
mRNA rather than providing a signal required for IL-2 transactivation (71).
Chapter 1 Discussion
Curing type 1 diabetes wil reqUire protocols that enable the successful
rejection response against a transplanted graft. It is the global suppression of this
transplantation of ~-islet cells into diabetic patients. Because existing transplantation
procedures have a significant negative impact on patient health, it wil be necessary to
develop protocols more benign than those currently used, preferably avoiding the use of
immunosuppressive agents altogether.
T cell activation is necessary to an effective immune response, including the
response that enables current transplantation procedures , but preferable would be to tailor
the immune system not to respond to the set of antigens found on a graft while
maintaining its competence toward any other foreign invader. It is conceivable that this
'''
tailoring process wil involve the incapacitation of graft-specific T cell clones, blocking
their ability to attack a graft and thus protecting the graft from immune rejection.
Inducing anergy in graft-specific T cells may aid in dampening their ability to reject a
graft.
There is an indissoluble relationship between IL-2 production, which is required
for T cell activation, and T cell anergy. It is useful to discuss the details of IL-
production in order to provide context for the known biochemical characteristics of
anergic T cells. The absence of an IL-2 signal upon T cell stimulation ushers a T cell into
an anergic phenotype, and once anergy is established, it is rendered incapable of IL-
production and therefore unable to proliferate. The characteristics of T cell anergy are
the focus of Chapter 2.
! ..
- Chapter 2 -
T Cell Anergy
History of Anergy
Clonal anergy is a T cell phenotype characterized by the inability to produce IL-
(72). Nossal and Pike borrowed the term ' anergy ' from Yon Pirquet in 1980 , to describe
a phenotype of hypo-responsiveness in B lymphocytes (73). Jenkns and Schwartz
described an analogous phenomenon in T cells resulting from stimulation with ECDI-
fixed splenocytes (74). Although numerous biochemical defects have been found in
anergic cells as the result of two decades of research, it has not yet been conclusively
determined what genetic programs are in place to institute and maintain the prevention of
Early anergy studies observed that ECDI-treatment of antigen presenting cells
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IL-2 production.
(APe) resulted in the establishment of an unresponsive phenotype in T cell clones, rather
than the expected stimulation (75). These studies were performed prior to the discovery
that CD28 signaling is required for full T cell stimulation, but it was hypothesized at the
time that the result of the ECD I treatment was the fixation of some ligand whose receptor
was required for IL-2 production. The studies also showed that chelation of calcium from
the culture medium with EGTA prevented the hyporesponsive phenotype completely.
Conversely, addition of the calcium ionophore ionomycin induced this unesponsive
phenotype. These studies implicated intracellular calcium signals as crucial to the
induction of anergy. Follow-up studies showed that MHC-containing planar lipids were
not capable of stimulating T cell clones, and also rendered the cells unresponsive to
subsequent stimulation with normal APC and antigen (76). This impaired stimulation
could not be overcome by the addition of exogenous IL- , IL- , IL- , IFN-y, or GM-
CSF, and could not be induced in the presence of cyc1osporine A, confirming the
importance of calcium in the induction of the hyporesponsive phenotype.
In the ECDI-fixation studies, the addition of allogeneic splenocytes to the
anergizing cultue restored the ability of the ECDI-treated syngeneic splenocytes to fully
stimulate the T cells. This finding provided evidence for the hypothesis that the
induction of the hyporesponsive state is due to the absence of some non-MHC restricted
signal that is obliterated by APC fixation with ECDI. Further studies found that the
addition of T cell clones to aCD3 antibody immobilized on plastic could induce an
identical anergic phenotype, confIrming the finding that stimulation of T cells through the
TCR alone results in a long lasting anergic phenotype rather than an activation response
(77). At the time these early studies were performed, it was not known which receptor or
Shortly following these studies , it was demonstrated that CD28 signaling was capable of
receptors on the T cell were capable of providing this necessary additional signal.
augmenting IL-2 production in conjunction with TCR signaling, and Jenkins was able to
block the induction of anergy in T cell clones by the addition of aCD28 antibody (78).
These studies demonstrated that it is possible to both induce anergy and stimulate T cells
Once anergy is established, it persists for seven to ten days if the cells are
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by selectively engaging specific receptors; they also provided models with which clonal
anergy and stimulation can be studied under controllable circumstances.
unmanipulated after induction (76). Studies by Beverly, et al (79), demonstrated that in a
ConA-induced anergy model (shown to be phenotypically similar to previously described
methods), the addition of exogenous IL-2 to the anergized cells restored their ability to
anergy: given that IL-2 is the primary growth cytokine for Thl T cells, what is the
proliferate at levels similar to those of previously untreated cells. These results were
confirmed by at least one other group (80). The results indicated that anergic T cells are
defective in their ability to produce IL- , but are capable of responding to exogenous IL-
2. This raises the important question as to what specifically leads to the induction of
relationship between proliferation and the induction of anergy? More specifically, does
the addition of the costimulatory signal to the TCR stimulus actively counter the
Later studies sought to investigate this phenomenon further, dissecting apart the
anergizing program that is established, or does it rather augment IL-2 production to levels
suffcient for proliferation, thus overcoming whatever conditions are present to maintain
anergy? This question was answered by blocking IL-2 signaling in T cells stimulated
with APC and antigen. aIL-2 and aIL-2R antibodies were used to neutralize IL-
activity, resulting in the prevention of T cell proliferation, as expected (81). Importantly,
after the cells were rested for five days , they were unresponsive to normal antigen-pulsed
APC. This result shows that T cells can be anergized even in the presence of a
co stimulatory signal, though it was not known at the time of these experiments whether
this was due to the absence of IL-2R signaling or cell cycle paralysis.
IL-2 receptor pathway with pharmacological agents whose activities block the cell cycle
in different phases. The important findings from these studies demonstrated a contrast
between the effects on cell cycle progression of hydroxyurea, a drug that arrests cell-
cycle progression after the cells reach S phase , and those ofrapamycin (sirolimus), which
arrests the cells prior to the G 17 S phase transition (82). In light of the body of prior
literature, Powell et al. proposed the existence of an anergy pathway parallel to the
stimulation pathway that negatively regulates T cell activation in the absence of IL-
signaling. In these studies, CD4+ T cell clones fully stimulated in the presence of
hydroxyuea were arrested after transition to the S phase, but after removal of the drug
they were not anergic upon restimulation. This was not the case when activated T cells
were treated with rapamycin. Rapamycin treatment permits T cells to make normal
amounts of IL-2 (83), but the IL-2 receptor signal is blocked at the mammalian Target of
Rapamycin (mTOR). When the rapamycin was removed from the stimulated T cells
they were unesponsive to antigenic stimulation: blocking the IL-2R signal anergized the
The importance of mTOR to anergy abrogation was later demonstrated by
cells. The importance of these data is that they show that anergy is not a passive
phenotype, and that its abrogation is dependent on signals downstream of the IL-
receptor.
stimulating T cell cultures in the presence of drugs that block the G17S phase transition
further implicate the IL-2 receptor signal as being primarily responsible for the reversal
by different mechanisms. These experiments concluded that the ability of rapamycin to
induce anergy was specific to its targeting of mTOR, rather than just its ability to block
cell cycle progression (84). This conclusion was confirmed by experiments showing that
IL- independent T cell proliferation is unable to reverse anergy (85). These findings
of anergy in T cell clones , and suggest the existence of a pathway parallel to the TCR-
dependent stimulation pathway, that, in the absence of IL-2 signaling, results in the
anergic phenotype.
Signal Transduction in Anergic Cells
The inability of anergic T cells to produce IL-2 has prompted investigators to
examine signaling differences between these and proliferation-capable lymphocytes.
Examination of other cytokines such as IL-3 (81) and IFN-y (75) revealed negligible
differences between the two. Importantly, it was found that frequently changing the
culture medium following anergy induction or productive stimulation resulted in anergy
in both cell populations (79). These data suggest that it any factors responsible for
establishing anergy are not soluble. It is possible that IL-2 production is prevented by the
presence of a biochemical block in signal transduction upstream of IL- gene
transcription, or that IL-2 transcription is actively repressed at its gene promoter. These
have been questions about the mechanism of anergy since its discovery. Neither question
has been definitively answered, although a number of biochemical changes have been
found in anergic cells.
There are many points in the IL-2 transcription pathway at which IL-2 production
studies it was deemed unlikely that NF AT was defective in anergic cells. Indeed, more
could be disrupted. As mentioned above, not only is the presence of calcium essential to
productive stimulation, but its chelation prevents anergy induction: therefore in early
recent studies have shown that NFATI-/- T cells cannot be anergized (59). Crucial for
IL-2 production is a complex of NFAT bound to AP- , consisting of jun and fos
heterodimers. Thus, the inactivation of jun and fos would result in impaired IL-
production, and possibly prevent NF AT from binding to crucial elements in the IL-
promoter region. Analysis of nuclear extracts from anergic cells showed a decrease in c-
fos and JunB protein expression levels (86), and promoter region studies showed that
transcriptional activity at both the AP- l and the NFAT/AP- l binding sites was impaired.
Follow up studies examining upstream members of the MAP kinase pathway showed that
ERK and JNK total protein levels were equal in anergic cells and stimulated cells, but the
enzmatic ability of both kinases was tested and found to be impaired in anergic cells
(87 , 88). Since ERK and JNK are intermediate steps in the MAP kinase pathway, the
question remained as to the upstream cause of these defects.
p21ras is a GTP-ase shown to be a crucial regulatory point for the MAP kinase
pathway (58). This makes it a clear candidate for studies hoping to identify a biochemical
switch toggling between productive stimulation and anergy. Studies contemporary to the
ERK and JNK experiments mentioned above discovered that the inactive state of these
kinases was due to a lack of phosphorylation on key activating tyrosines (89). The
investigators pursued the cause of this by examining the abilty of Ras to bind GTP, the
primary indicator of its activation status. They found that Ras is unable to bind GTP in
anergic cells whereas previously stimulated cells could activate Ras normally. I;'
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normally. This is perhaps the same mechanism by which these reagents can reverse
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anergy. As to the cause of this inability of anergic cells to activate Ras, a number of
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proteins known to regulate Ras including Shc, Grb- , and mSOS were examined. Their
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protein levels and activation statuses were found to be equal in anergic and stimulated
cells (89), ruling out any specific role for them in anergic cell populations. Crespi et al.
further investigated the role of defective Ras in anergy by expressing a constitutively-
active Ras in T cells, showing that they were stil able to be anergized despite the reversal
of the ERK phosphorylation defect (90). Interestingly the constitutive activation of Ras
enables anergic cells to produce IL-2 in response to ionomycin alone, bypassing the need
for PMA stimulation. This suggests that a major role of PMA in productive stimulation
is the activation of Ras. It remains to be determined by what mechanisms anergic cells
hold Ras in an inactive state. It has been proposed that a yet-unidentified RasGAP is
active in anergic cells, thwarting upstream attempts to activate Ras by driving the
autocatalytic ability of Ras to cleave GTP to GDP (72). The identification of such a factor
would possibly provide a point for therapeutic manipulation of anergic T cells, and is
currently the goal of many studies. A depiction of the known signaling defects in anergic
T cells is shown in Figure 5.
Figure 5
Legend for Figure 5
Anergic T cells are unable to make IL-2. It is possible that this is a result of
defects found in signaling pathways known to be required for productive T cell
stimulation. It is believed that the primary barrer to IL-2 production in anergic cells is a
defect in the MAP kinase pathway, specifically the inability to activate Ras, ERK, and
JNK.
Regulatory T cells, Anergy, and Immune Regulation
The concept of T cells with suppressor or regulatory capabilities has reemerged in
recent years, and has gained a great deal of momentum since the discovery that
CD4 CD25+ cells have the ability to regulate other T cell populations. For a time, the
existence and relevance of T cell-mediated active suppression was controversial, but
studies have demonstrated well the importance of regulatory T cells in peripheral
tolerance, transplantation, and autoimmunity (91). Interestingly, studies have shown that
not only do regulatory T cells have the ability to suppress distinct populations of T cells
but they also manifest signs of anergy. It is possible that the anergic phenotype is
important to the function of regulatory T cells, and learning more about anergy and the
role that regulatory T cells play in peripheral tolerance may aid in developing safer
methods of inducing transplantation tolerance.
Early studies demonstrated the importance of regulatory T cells in autoimmune
models by periodically transfusing whole blood from non-diabetic rats into diabetes-
prone strains and preventing diabetes in these rats (92). Importantly, depleting the T cells
from these transfusions reversed the protective effect (93). Further studies explained this
reversal by identifying a population of W3/25+ T cells whose presence in blood
transfusions protects the diabetes-prone BB/W rat from autoimmunity. This led to the
speculation that a contributing factor to diabetes in the diabetes-prone rat is a defect in
this cell population (9).
Recently, the number of studies focused on regulatory T cell populations has
increased dramatically, and this cell population has been found to be important to many
facets of autoimmunity, natural peripheral tolerance, tumor immunity, and transplantation
(94). A result of this increased attention has been the discovery of a number of
subpopulations of regulatory T cells. These subpopulations include those emerging from
the thymus expressing CD4 and CD25 , which are referred to as naturally occurring
CD4+CD25+ Treg cells; Treg that do not express CD25 as a surface marker; and IL-
producing Treg cells (95).
The relationship between these populations and their individual roles in immune
regulation has not yet been fully determined. It has been shown that the transcription
factor FoxP3 functions in some capacity as a master regulatory switch for the
development of Treg cells , and that its forced expression in naIve T cells confers on them
the properties of a regulatory T cell (96). Defects in F oxP3 have been found in
IPEXlXLAAD mice, which develop an X-linked lymphoproliferative disease caused by
defective T cell tolerance , supporting its importance in immune regulation.
Although the details of how regulatory T cells exert their suppressive effects are
not fully known, TGF-~ has recently been shown to play an important role. Freshly
isolated naIve CD4+ cells treated with TCR stimulation and exogenous TGF-~ develop
the ability to suppress CD4 CD2Y responder cells in a contact-dependent fashion. The
development of this ability may be due to the increase in their cell surface expression of
TGF-~. (97). It has also been shown that TGF-~ treatment of naIve CD4 CD25- cells
increases their expression of Foxp3 , suggesting their conversion to regulatory T cells
(98). The importance of TGF-~ is not limited to its ability to induce regulatory cell
properties; it has been shown to play an important role in the actual suppression process.
This has been demonstrated in part by studies showing that cells without the ability to
respond to TGF-~ are not subject to suppression by naturally arising regulatory T cells
(99).
It is possible that the anergic phenotype is important for the proper functioning of
regulatory T cells. Sakaguchi has shown that naturally arising CD4 CD25+ regulatory T
cells are phenotypically anergic , in that they do not proliferate in response to TCR
stimulation (100). Rather than eliciting a proliferative response as it would for a naIve T
cell, triggering the TCR on a CD4 CD25+ suppressor cell activates its capacity to
suppress the proliferative response of CD4 CD25- T cells in its proximity. Other studies
With regard to biochemical signaling, similarities have been found between the
have found the anergic and suppressive phenotypes in the same cell population - these
cells don t proliferate or produce IL- , and have the ability to prevent proliferation in
nearby CD4 CD2Ylymph node cells (101).
form of anergy seen in regulatory cells, and the form seen in cells anergized by
conventional methods, but the extent of their equivalence remains to be seen (102).
Apart from the fact that there may be phenotypic similarities between these populations
subsequent costimulation. This form of suppression has been found to correlate with one
of cells (Figure 6), it has also been shown that regulatory T cells may exert their
suppressive effects not only by transiently preventing proliferation in other populations of
T cells, but by inducing an anergic phenotype that persists even in the presence of
of the factors currently thought to be essential to anergy induced by traditional anergizing
methods (103).
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Anergic cells and regulatory T cells share characteristics. Both cell populations
are refractory to TCR stimulation, and neither population is able to make IL-2 in a
co stimulatory environment.
The importance of suppressor T cells in providing protection against
autoimmunity has been known for some time. Recently, their immunoregulatory
capabilities have been implicated in transplantation models functioning both
systemically (104) and at the site of a tolerated allograft (105). Increasing our knowledge
of these types of cells may not only provide insight into preventing diabetes; there is also
the chance that learning to direct the ability of these cells to suppress specific sets of
antigen-responsive immune cell populations may provide the opportnity to cure diabetes
by facilitating peripheral tolerance without general immunosuppression.
In vitro and in vivo models for T cell anergy
When Jenkins and Schwartz first began to examine T cell anergy, they stimulated
There have been a number of models developed to study anergy. Though they are
mostly dissimilar in the means by which they induce anergy, the end result is the same:
the inability to produce IL-2 and proliferate upon antigenic stimulation. The following
section describes a number of methods of anergy induction in vitro and in vivo.
Immobilized Anti-CD3 Antibody
T cell clones with splenocytes fixed with ECDI (74). Subsequent experiments led to the
discovery that T cell clones could be anergized with immobilized aCD3 antibody, and
were productively stimulated when soluble aCD28 antibody was added to the culture
medium in addition to aCD3 (77). The in vitro model we have chosen to study is the T
cell clone A.E7 , provided by the Schwartz laboratory. A.E7 T cells were derived from
BlO. mice immunized with pigeon cytochrome C and carried by stimulation and
opportnity to use pure clone cultures is invaluable for answering biochemical questions.
expansion every two weeks, by a method modified from that described previously (106).
The ability to maintain a pure population of cells throughout an experiment provides the
opportnity to lyse cells for Western blotting or RNA purification for RT-PCR, which
would not be possible if a model involving the use of APCs was chosen. Although the
use of antibodies for stimulation is less physiological than some other models, the
Altered Peptide Ligands
Shortly following the studies demonstrating the effect of fixed splenocytes on T
cell activation, studies using modified TCR ligands (alterations in the cognate peptide
sequence) showed that T cells could be anergized even in the presence of co stimulation
(107). By changing amino acid residues in the peptide sequences, the authors could
weaken TCR signaling suffciently to induce a state of hypo-responsiveness similar to
that seen with fixed antigen presenting cells. It was hypothesized that in this model of
anergy induction, it was not the lack of a signal through costimulatory receptors that
determined the activation status of the cell, but rather the inability of the TCR to provide
suffcient signal to make IL- , even though full costimulation was present. This form 
anergy induction has recently been shown to have potential therapeutic value in the
treatment of autoimmunity; the use of altered peptide ligands in a myasthenia gravis-
susceptible mouse strain resulted in the amelioration of autoimmune symptoms and a
phenotypic change in lymphocytes, which became anergic (108). It was subsequently
shown that this hypo-responsiveness was due to altered CD3- chain phosphorylation and
Ionomycin is a calcium ionophore that triggers the release of calcium from the
an inability to recruit phosphorylated ZAP70 to the TCR signalosome (109).
Ionomycin
endoplasmic reticulum and an influx of calcium from the extracellular space (110). The
importance of the calcium pathway to anergy induction has been shown (77) and is
substantiated by the fact that a strong calcium signal in an otherwise unstimulated cell
can confer an anergic phenotype to a T cell (59, 111). This method of anergy induction
has proven effective in T cell clones and ex vivo purified CD4+ T cells (112). There is
some evidence that this method anergizes cells by a mechanism different from that of
conventional TCR-signal-only anergizing methods (59).
Division-Arrest Anergy
An IL-2-refractory model of anergy has been described by Wells and Turka, who
stimulated CFSE-stained CD4+ T cells ex vivo and found a correlation between a lack of
initial proliferation and the entr of the cells into a hyporesponsive state (113). This fits
with currently understood models of anergy: stimulated cells that don t proliferate
become anergic. Interestingly, unlike most other forms of anergy, the anergic
subpopulation of cells does not respond to exogenous IL- , but can be restored to full
reponsiveness by treatment with PMA and ionomycin. It has not yet been shown what
specific disconnect exists biochemically in these cells to prevent the IL-2 receptor from
delivering a proliferative signal, but the authors do correlate the presence of the
phenotype with increased expression of p27kipl , a known cell-cycle inhibitor implicated
in other forms of anergy (114). Whether the presence ofp27kipl is simply a correlation or
the cause of cell-cycle inhibition in this case is not discussed by the authors and is not yet
known.
Intravenous Peptide Tolerization
The model of in vivo anergy induction most analogous to anergy observed in cell
clones was developed by Jenkins while in the Schwartz laboratory (72). This model
consists of the adoptive transfer of small numbers of transgenic cells , identifiable by a
clonotypic antibody, into a non-irradiated, immune competent, syngeneic recipient. After
transfer, cells are tolerized with an intravenous injection of their cognate peptide, or
immunized with an injection of peptide with lipopolysaccharide. Cells are permitted to
circulate for twelve days and are then purified out of the spleen and lymph nodes for
F ACS staining and rechallenge with peptide (115). There is at least one example in the
literatue of this model being used to confirm the function of a proposed' anergy factor
The ability of mitogenic anti-CD3 antibodies to prolong graft survival has been
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(112), and the cells exhibit behavior very similar to that in the above described model of
anergy induction in vitro.
Non-Mitogenic Anti-CD3
shown (116- 118), but in many cases the acute activation of immune cells prior to the
tolerizing effect of the antibody proved problematic (119). This led to the search for ways
to make this reagent less mitogenic and more tolerogenic , a goal achieved by decreasing
the affnity of the antibody Fe region for Fey-receptors (120, 121). Further investigation
into the consequences of this alteration showed that this decreased ability to bind 
for full TCR activation. This prevented the T cells from making suffcient IL-2 to drive
receptors resulted in impaired cross-linkng of the TCR complexes, an event necessary
cell proliferation, and subsequently led them into an anergic state from which they could
be rescued with exogenous IL-2 (122). In contrast to other anergy models , this form was
found to manifest deficient TCR signaling, insuffcient PLC-y activation
, and an impaired
calcium flux in response to TCR triggering. Biochemically, it appears that the type of
anergy induced by non-mitogenic aCD3 is somewhat distinct from the clonal anergy first
These findings suggest that in some capacity, anergy may be an important
described by Schwartz, et. aL
The use of non-mitogenic aCD3 antibody in the regulation of peripheral tolerance
has proved to be promising (123- 126). The precise mechanism by which aCD3 antibody
is able to modulate autoimmunity remains controversial, but it has been proposed that it
is stimulating a population of regulatory T cells (127) or inducing a functional tolerance
similar to anergy (128, 129).
contributory mechanism to successful transplantation, and thereby merits study to further
elucidate the biochemical nature of the phenotype.
Proposed Anergy Factors
Early studies of anergy hypothesized that a unique signaling pathway might be
involved in its orchestration. This idea was first proposed first by Quil and Schwartz
who demonstrated that cyclohexamine treatment could prevent the induction of anergy
(72) (Figure 7). The findings were extended by Powell, et al (82), who showed that cell
cycle progression from G 1 to S phase incapacitates some proposed molecular factor or
pathway whose presence is necessary for the anergic phenotype to persist. Many studies
have attempted to characterize this putative pathway and identify these factors. The
following is a summary of these attempts.
Boussiotis et al. found that p27kipl was specifically expressed in hypo-responsive
cell populations both in vitro and in vivo and fuher showed that p27kipl
overexpression prevented jun activation in anergic cells, resulting in defective AP-
transcription and IL-2 production (114). Subsequent to these studies, it was shown that
the amounts of IL-2 required to reduce p27kipl levels were far lower than those required
to reverse anergy, and that cells from p27kipl /- mice were fully capable of being
anergized, callng into question its importance to the anergic phenotype. It is interesting
to note that Boussiotis employed overexpression of p27kipl to demonstrate IL-2 protein
suppression, and later studies that reduced the amount of p27kipl expression to more
physiological levels did not suppress IL-2 production upon T cell rechallenge (130).
Boussiotis continued her studies and subsequently discovered that Tob- , a
known cell cycle inhibitory gene, is expressed in both anergic and quiescent populations
of T cells, and that its depletion with antisense oligonucleotides reduced the need for
TCR
Figure 7
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Legend for Figure 7
The T cell receptor signals via two distinct pathways. If co stimulatory signals are
present, they are able to synergize with the TCR activation pathway, resulting in IL-
production and proliferation. In the absence of co stimulation, a second pathway institutes
the anergic phenotype, which is then capable of preventing IL-2 production, even in the
presence of subsequent costimulation.
costimulation in making suffcient IL-2 to drive proliferation. These studies showed that
Tob- l acts not by inhibiting the MAP kinase pathway, whose defects in anergic cells
have been well demonstrated, but rather by collaborating with Smad to bind the - 105
negative regulatory element of the IL-2 promoter (131). Despite their seeming relevance
these studies have not been followed up, and no furher details regarding the role of Tob-
1 in anergy have appeared in publication since these studies.
Another proposed anergy factor is lymphotactin, a cytokine whose high
expression has been reported in unresponsive Th1 T cell clones. It was initially proposed
to be a member of the putative anergy pathway, but it was subsequently found that this
protein is down-regulated by CD28 signaling prior to IL-2 production. It is likely that
lymphotactin was not pursued in this context because the putative anergy factor proposed
by Powell would be down-regulated by IL-2R signaling after the production of IL- , not
by CD28 signaling prior to IL-2 transcription (132).
The role of E3 Ligases in T Cell Anergy
Despite the numerous studies claiming to have identified the sought-after ' anergy
factor , the precise biochemical picture of anergy continues to elude us. The majority of
studies mentioned above claim to have discovered a factor crucial to the anergic
phenotype, yet none has definitely demonstrated that their factor is essential to anergy,
and each factor is implicated indirectly at best. An exception to this trend is a class of
signaling molecules termed E3 ubiquitin ligases, whose functions are necessary for
shutting proteins to the proteasome for degradation. Recent studies have been quite
definitive in demonstrating the importance ofE3 ligases in anergy.
The importance of the proteasome degradation pathway to anergy has been well
ilustrated in the past few years , beginning with the discovery of GRAIL (Gene Related
to Anergy in Lymphocytes), a novel E3 ligase (133). Briefly, the proteasome degradation
pathway is a post-translational regulatory mechanism that disposes of proteins by
mechanically breaking them down. This pathway is initiated by an EI ubiquitin-
activating enzyme that charges a ubiquitin molecule so it can bind an E2 ubiquitin carrier
protein/E3 ubiquitin ligase complex (134). The E3 ubiquitin ligase can then transfer the
ubiquitin to the target protein, labeling it to be shuttled to the proteasome where it is
degraded.
GRAIL was found in an in vitro artificial APC anergy model to be highly
expressed in anergic T cells after four hours of stimulation, and almost undetectable in
unstimulated T cells (133). As an alternative method of anergy induction, cells were
anergized with ionomycin and it was determined that GRAIL expression peaked after six
hours of ionomycin treatment and had decreased significantly by eighteen hours
suggesting a very early window of activity for GRAIL in the anergy induction process
(112). Constitutively-expressed GRAIL was shown to inhibit IL-2 production in T cell
hybridomas , an effect successfully abrogated by mutating GRAIL' s RING domain, thus
abolishing its abilty to transfer ubiquitin molecules to other proteins. Follow up studies
showed GRAIL to be capable of inhibiting T cell proliferation in stably-transduced
GRAIL-expressing cells ex vivo (112). These studies further showed that GRAIL-
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expressing CD4+ T cells manifested signs of being anergic, which were reversed upon
mutation of GRAIL' s RING domain.
This first example of the potential importance of E3 ligases ushered in a new era
anergy research (135). Until the discovery of GRAIL, it was not known what
prevented proliferation early in the anergy induction phase, permitting the full
establishment of the phenotype. After the GRAIL studies were published, another group
published studies using ionomycin to induce anergy and showed that GRAIL, along with
two other E3 ubiquitin ligases, Itch and Cbl- , was transcriptionally up-regulated as a
result of strong calcineurin activation (136). These studies further demonstrated the
importance of E3 ligases in anergy induction by showing a correlation between the
transactivation of these factors, primarily Itch and Cbl- , and the degradation of a number
of signaling factors known to be crucial for successful TCR signaling. Among these is
PLC- , which is responsible for the cleavage of PIPz into IP and DAG, an early event
in the TCR signaling pathway. The authors also showed the degradation of PKC- , a
regulatory point in Ras and MAP kinase pathway activation. It has also been speculated
that this E3-liagse-driven degradation program also prevents T cell activation by
weakening the interaction between the T cell and the APC, thus cutting short the time
required for full signaling (137). These correlations suggest that the presence of E3
ligases in the early induction of anergy preempts successful T cell receptor signaling due
to their ability to direct crucial signaling proteins such as PLC-y I and PKC-S to the
proteasome for degradation rather than permitting their participation in T cell signaling
cascades. The importance of Cbl-b to anergy induction was confirmed in vivo by studies
showing a lack of proliferation in peptide tolerized adoptive transfers of Cbl-b+/+ CD4+
T cells, an effect reversed when the same experiments were done with Cbl- /- cells
(138). A simplified depiction of the role of E3 ligases in anergy induction is shown in
Figure 8.
The discovery of the importance of E3 ligases in anergy has provided some
insight into the early events in T cell signaling that dictate the decision between
productive stimulation and anergy. It is likely that the predominant role of these factors
is very early in the signaling process , and their activity is one of the criteria by which a
cell chooses to become anergic rather than proliferate and expand. Further studies of
these and other E3 ligases wil aid in understanding the importance of E3 ligases to the
immune response as a whole.
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Legend for Figure 8
E3 ligases prevent IL-2 production early in anergy induction. A. PLC-y1 and
PKC- , known to be important in the IL-2 production pathway, are activated upon TCR +
CD28 stimulation. B. The presence of E3 ubiquitin ligases early in the anergy induction
process leads to ubiquitination ofPLC-y1 and PKC- , resulting in their degradation. This
disrupts IL-2 production and proliferation.
Anergy and Peripheral Tolerance
Studying the biochemical characteristics of anergic cells provides interesting
insight into T cell function, but against a physiological backdrop studying anergy is only
useful to the extent that it fits into the dynamics of the immune system as a whole. There
have been studies offering evidence that anergy may be an active process in numerous
instances of peripheral tolerance , including the dampening of allo-immune responses.
Studies using primary cells to investigate the CD4+ T cell response to allo-splenocytes
have shown a significant decrease in allo-responsiveness when aCD154 (CD40L)
antibody was included in the MLR cultue, an effect abrogated by the addition of
mitogenic doses ofIL-2 to the culture (139).
It is well established that aCD 154 antibody treatment concurent with a donor
specific transfusion (DST) prolongs allograft survival (140- 142); the mechanism by
which this occurs is stil being investigated. One function of CD40 on APCs is to signal
the up-regulation of costimulatory molecules, and it is tempting to speculate that graft
survival prolongation is due to the induction of an anergic state in T cells that recognize
graft antigens. The proposed mechanism of aCD154 treatment is shown in Figure 9. 
remains to be seen whether anergy is an active process in the induction of tolerance seen
with aCD154 treatment.
Clinical transplantation studies have shown evidence suggesting a role for anergy
in graft tolerance. Peripheral CD4+ T cells purified from the blood of patients with
tolerated kidney grafts (successful engraftment for at least one year) were hyporesponsive
to antigenic rechallenge, and the proliferative response of these cells was dramatically
Figure 9
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Legend for Figure 9
A. Tolerance induction with aCDl54 mAb in the context of the three-signal
hypothesis of T cell activation. When the TCR is engaged by an MHC molecule, the T
cell upregulates CD154 , which engages CD40 on the APC and induces the up-regulation
of B7 family members. These are now able to deliver a signal through CD28 , the result
of which is T cell activation. B. The use of aCD154 monoclonal antibody prevents the
up-regulation of B7 , rendering the APC incapable of fully stimulating the T cell.
increased following treatment with IL-2 (143). This is reminiscent of a conventionally
anergized cell' s response to IL- , and suggests that there may be a functional role for
anergy in transplantation tolerance. A very recent study has shown what appears to be a
definitive link between anergy and graft tolerance (144). The authors stimulated
recipient splenocytes with donor splenocytes and added aB7. 1 and aB7.2 antibodies to
block costimulation of the recipient T cells. After culture, the cells were transfused back
into the recipient followed by a kidney transplant, which engrafted successfully following
a short course of immunosuppression. The authors suggest that some propert of the
anergic cells generated by blocking co stimulation in the mixed lymphocyte reaction is
what enabled the successful engraftment. It wil certainly be necessary to further
characterize the nature of the transfused cells prior to any emphatic claims.
Chapter 2 Discussion
T cell anergy may play an important role in peripheral tolerance, and it may be
possible to anergize T cells in order to quell an undesired immune response. It is clear
that T cell anergy is a complex phenotype involving a biochemical disconnect in the IL-
production pathway. This break in signaling is likely due to the presence of anergy-
specific proteins whose functions in some way impede proper T cell signal transduction.
I propose that it is possible to identify these proteins and demonstrate their importance to
the anergic phenotype , gaining additional insight into the biochemistr of anergic cells
and potentially providing markers for the identification of anergic cell populations.
Perhaps more importantly, knowledge of these anergy factors could provide insight into
how to direct specific populations of cells into a state of anergic hypo-responsiveness
possibly enabling us to tailor the immune response to react to some antigens and not to
others.
Thesis Goals and Specific Aims
Given the evidence that there is a distinct biochemical pathway that establishes
the anergic phenotype in T cells, it stands to reason that the members of this pathway
might be identified and their expression levels modulated in order to control T cell
responsiveness. With this in mind, the following specific aims were addressed:
Specifc Aim Test the hypothesis that there is a TCR-dependent anergy
pathway. Utilize Affymetrix RNA transcriptional profies to identify factors specifically
expressed in anergic Tcell populations.
Specifc Aim 2: Confirm the importance of selected anergy factors by depleting
their protein levels in anergic cells with siRNA to test for the reversal of the phenotype.
Specifc Aim 3: Test various models of tolerance for the involvement of factors
identified in Specifc Aims 1 and 2.
Materials and Methods
Animals
B10.BR (H2 ), Balb/c (H2 ), D011.10/Balb/c (I-U ), and C57BL/6 (H2 ) mice
were purchased from The Jackson Laboratory (Bar Harbor, Maine). DOl1.lO/Balb/c is a
transgenic strain of BALB/c mice whose T cell repertoire is restricted to a single T cell
receptor cognate to OVApeptide 323-339. They are hereafter referred to as DOl1.10.
All animals were certified to be free of Sendai virus, pneumonia virus of mice
murine hepatitis virus, minute virus of mice, ectromelia, LDH elevating virus, mouse
poliovirus, Reo-3 virus, mouse adenovirus, lymphocytic choriomeningitis virus
polyoma Mycoplasma pulmonis and Encephalitozoon cuniculi. They were housed in a
specific pathogen free facility in microisolator cages, and given autoclaved food and
acidified water ad libitum. All animal use was in accordance with the guidelines of the
Institutional Animal Care and Use Committee (IACUC) of the University of
Massachusetts Medical School and recommendations in the 
Guide for the Care and Use
of Laboratory Animals (Institute of Laboratory Animal Resources, National Research
Council, National Academy of Sciences , 1996).
E7 T Lymphocytes
The A.E7 cell line (a gift from Ronald Schwartz s lab , NIH) is a clonal population
of CD4+ T lymphocytes whose T cell receptor recognizes residues 81- 104 of the pigeon
cytochrome C (PCC) protein presented in the context of an IE MHC class II molecule.
Cells were carried in a medium consisting of 50% RPMI 1640 (Invitrogen #11879-020)
and 50% EHAA (Biosource #PI20-500), with 10% fetal bovine serum (Hyclone
#SH30070.03) and supplemented with 0. 1% 1000X Mercaptoethanol (Gibco #21985-
023) and 2mM L-glutamine!20 U/ml penicilln/20 g/ml streptomycin (Sigma-Aldrich
#G 1146). To prevent activation of the complement casacade, fetal bovine serum was heat
inactivated at 56 C for 30 minutes. The medium was 0. M sterile-fitered before use.
The A.E7 is not a transformed T cell line, and therefore needs to be stimulated
every two to three weeks to remain viable. To carr the line, RBC-depleted BI0.
(H2 ) splenocytes were Cesium- 135 irradiated with 3000 rad and added in culture to a
subpopulation of A.E7 at a 10: 1 ratio (B 1 0.BR:A.E7). The stimulation culture was
pulsed with 8 M whole cytochrome C (from pigeon breast muscle , Sigma #C4011) and
incubated for 40-48 hours at 37 C 5% CO . Following stimulation, cells were expanded
1:40 (cells:medium) in 10% FBS/RPMI 1640/EHAA (referred to hereafter as growth
media) supplemented with 15 U/ml recombinant mouse IL-2. Cultures were incubated
for 10 days following addition of IL-2 to allow proliferation and return to quiescence.
Every six to eight weeks, a stock vial of A.E7s was thawed from liquid Nz storage and
stimulated by the above methods.
Anergy Induction and Stimulation of E7s
To induce anergy in A.E7s, anti-CD3 antibody (clone 145-2C11 , BD Pharmingen
#553057) was immobilized on plastic tissue culture flasks or dishes at a concentration of
g/ml in Dulbecco s PBS (Gibco #14040075). Flasks were incubated at 37 C for at
least one hour after addition of antibody, or at 4 Covernight to permit coating of the
plastic. After coating, plates were washed three times with PBS to avoid carrover of
any soluble anti-CD3. Viable A.E7 cells were purified over a Lympholyte M gradient
(CedarLane #CL5030), washed twice in 1% ~FBS/RPMI1640/EHAAlPSQ (referred to
hereafter as wash medium) and brought into suspension in growth medium. Cells were
plated at a density of lx10 /ml and incubated at 37 C for 12-16 hours. As a control
population, used as a proliferation-capable comparison to the anergic A.E7s, a sub-
population of cells was treated as above and supplemented with 1 ~g/ml anti-CD28
antibody (clone 37. , BD Pharmingen #553295) to provide costimulation. After 12-
hours of incubation, cultue flasks were placed on ice to suspend receptor signaling. The
supernatant was removed to a centrifuge tube and replaced with wash medium, and the
cells were scraped to remove them from the plate-bound antibody. The cells in medium
were then removed to a fresh centrifuge tube, and the flasks were rinsed with wash
medium, which was added to the same centrifuge tube as the scraped cells. Cells were
washed twice in wash medium and added to new tissue culture flasks at 1-2x10 /ml.
Cells were left un-manipulated in culture for at least five days to permit the full induction
of anergy before experimental use.
To assess the degree of hypo-responsiveness induced by the anergizing stimulus
Restimulation of Anergic Cells
anergic A.E7 cells were rechallenged in a 96-well plate with BlO.BR splenocytes. To
prepare the APCs, BlO.BR spleens were homogenized with frosted slides, fitered
through a 100-~m sieve, and treated with Gey s solution to lyse the red blood cells. The
remaining leukocytes were then washed twice with wash medium and irradiated with
3000 rads in a cesium gamma- irradiator. The cells were washed again with wash
medium, resuspended in growth medium, and counted. Untreated, anergic, and
costimulated A.E7 cells were added to the splenocytes at a ratio of 5:1 (BlO.BR:A.E7)
and triplicate wells were treated with increasing doses of PCC protein (Sigma) ranging
from a starting concentration of 0.6 ~M and doubling each triplicate to a final
concentration of 20 ~M. A.E7s were stimulated for 64 hours. Fort-eight hours after the
start of stimulation, 1 ~Ci of eH)-thymidine was added to each well in order to measure
DNA synthesis, an approximation of cellular proliferation. At 64 hours, the contents of
each well were transferred to a glass fiber fitermat (Wallac #1450-421) in a Tomtek
Mach II Harvester 96 and dried for one hour under a heat lamp. After drying, the filter
was heat-sealed in a Perkin Elmer sample bag (#1450-432), coated with ~-scintilant
(Perkin Elmer #1205-441), and counted on a Microbeta 1450 Trilux microplate counter.
Transfection of siRNA
Short inhibitory RNA duplexes (siRNA) were purchased from Dharmacon RNA
Technologies (Layfayette, Colorado) in the form of individual duplexes (Egr2-1 and
Egr2- , and SCR control siRNA) or SMARTPool formulations (Egr2, Neuritin, PACl
AK011178 , DGKz, and PD- l). SiRNAs were resuspended in RNAse- free HzO (provided
by Dharmacon) at a concentration of 1 nmoll~l. A.E7 cells were centrifuged to pellet and
resuspended at a concentration of 30-60x10 in growth medium. 500 ~l of cell culture
was added to a OA-cm cuvette (BioRad #165-2091) and incubated on ice for 10 minutes.
Following incubation, 5 nmol of siRNA (single duplexes) or 20 nmol of siRNA
(SMARTPools) was added to the cuvette, which was immediately electroporated with
310 V at a capacitance of 950 ~Fd in a BioRad Gene Pulser II electroporator. Cells were
placed back on ice to recover for 5- 10 minutes, added to 3-6 ml of growth medium per
cuvette, and incubated at 37 C 5% COz for at least 48 hours before use in experiments.
siRNA Sequences
siRNAs with the sequences gug acc acc uua cua cuc adt dt (Egr2- 1) and
gtt tgc cag gag tga cga adt dt (Egr- 2) were used to direct the degradation of Egr-2 mRNA
transcripts. An siRNA with the sequence cag ucg cgu uug cga cug gdt dt was used as a
non-specific control. The siRNA duplexes makng up the PD- l (NM 008798)
SMARTPool were (sense strand) duplex 1: uau cau gag ugc ccu agu guu; duplex 2: gau gcc
cgc uuc cag auc auu; duplex 3: gaa cug gaa ccg ccu gag uuu; duplex 4: gca agg acg aca cuc
uga auu.
Western Blotting
To assess protein levels, cells were washed in PBS , lysed in SDS lysis buffer (130
~M Tris-Cl pH 6. , 4% SDS , 10% glycerol), and immediately boiled to prevent protease
degradation. 5- 1 0 ~l of boiled lysate was saved for quantitation by BCA assay (Pierce
#23225), and calculated by comparison to a BSA standard curve. Samples were reduced
with 14M ~-mercaptoethanol, stained with 0. 1 % bromophenol blue, and boiled for 5-
minutes to denature any residual tertiary protein structure. Samples were loaded in equal
total protein quantities (10 - 20 J.g) onto a 4% acrylamide Tris-CI stacking gel poured on
top of a 10% acrylamide Tris-Cl resolving gel in a BioRad Mini-Protean II Western blot
apparatus. Samples were ru for 1 hour at a voltage of 150 V at a constant current of 500
mA. After resolution, protein samples were transferred from the gel to an Immobilon-
PVDF membrane (Milipore #IPVH07850) previously activated for 15 seconds with
100% methanol, and washed for one minute in deionized water. Samples were
transferred for 1 hour at a voltage of 100 V with a constant current of 500 mA.
For Egr-2 blotting, membranes were blocked for 30 minutes with 5% nonfat milk
(Biorad #170-6404) dissolved in TBS with 0. 5% Tween-20 (TBS-T). Primary antibody
against Egr- (Covance #PRB-236P) was diluted 1:200 in 5% milk/TBS-T and
membranes were incubated with shaking at room temperature for 1-2 hours or at 4
overnight. After primary antibody incubation, membranes were washed twice in 200 ml
TBS-T and incubated in anti-rabbit secondary antibody (Chemicon #AP132P) conjugated
to horseradish peroxidase diluted 1: 10 000 in 5% milk TBS- T for 30 minutes with
shaking at room temperature. Following secondary antibody incubation, membranes
were washed twice in 200 ml TBS- T and developed in Western Lightning PIus
Chemiluminescence reagent (Perkin Elmer #NELI03) or SuperSignal Pico Enhanced
Chemiluminescence reagent (Pierce #34077) for one minute. BioMax Light or BioMax
XAR (Kodak) fim was exposed to the developed blot for times ranging from 1 to 30
For PD- l blotting, samples were prepared, resolved, and transferred as above, and
minutes and developed in a Kodak X-OMAT developer.
blocked in 8% BSA TBS- T for 30 minutes. Membranes were then washed twice in 200
ml TBS-T and incubated with shaking in 0. J.g/ml anti-mouse-PD- l antibody (R & D
Systems #AFI021) overnight at 4 , then washed twice again with TBS-T. Membranes
were incubated in chicken anti-goat-HRP antibody (Chemic on #API63P) diluted
1:50 000 in TBS-T for 30 minutes with shaking at room temperature, then washed and
developed as above.
Flow Cytometry
FITC-conjugated anti-PD- l antibodies (#11-9981 , clone RMPI-30) were obtained
from eBiosciences. PE- conjugated anti-DOl1.10 TCR (#MM7504 clone KJ1-26)
antibodies were obtained from Caltag Laboratories, and APC-conjugated anti-CD4
(#553051 , clone L3T4) was obtained from BD Pharmingen. For staining, RBC-Iysed
primary splenocytes and lymphocytes were washed in PBS with 1% BSA, 0. 1 % sodium
azide. Fc receptors were blocked for 10 minutes with FcyII/II antibody (clone 2.4G2
Invitrogen #553142), washed, and treated with diluted conjugated antibodies for 1 hour
on ice in the dark. FITC-conjugated anti-PD- l antibody was diluted 1:10 in PBS with
1% FBS , and PE-conjugated anti-DOl1.10 TCR antibody was diluted 1:5 in PBS with
1 % FBS. APC conjugated anti-CD4 antibody was diluted 1 :25 in PBS with 1% FBS.
Cells were washed and fixed in a solution of PBS- l % paraformaldehyde, and read on a
BD F ACScan flow cytometer.
qRT-PCR
Total RNA was purified from A.E7 cells over an RNeasy Mini column (Qiagen
#74104) according to the manufacturer s instructions. A QiaShredder (Qiagen #79654)
colunm was used to homogenize the sample prior to purification. cDNA was transcribed
with oligo-dT 15 primer and Transcriptor brand reverse transcriptase (Roche
Green I PCR Kit (Roche 11988131001) and primers amplifying a 100- 1000 base pair
#03531287001) Real time PCR was performed in a LightCycler (Roche) using a SYBR
region of the transcript of interest. PD- l transcript levels were quantitated by amplifying
the region flanked by primers 5' CCG CTT CCA GAT CAT ACA G 3' and 5' CTC TGG
CCT CTG ACA T AC TTG 3' . Egr-2 transcript levels were quantitated by amplifying the
was normalized to HPRT or GAPDH.
region flanked by primers 5' TGA CAG CCT CTA CCC GGT GGA 3' and 5' GTG GAT
GGC GGC GAT AAG AA T 3' . Unstimulated or ConA-stimulated mouse splenocytes
were used to generate a standard curve and calculate units of expression. Fluorescence
ELISA
To measure IL-2 cytokine levels in culture supernatants, 96 well plates were
coated (100 ~lIwell) with purified rat anti-mouse IL-2 capture antibody (BD Pharmingen
#554424) diluted 1:500 in O. IM Na HP04pH 9. Plates were incubated overnight at 4
capture antibody was removed, and wells were washed twice with PBS-T. Wells were
then blocked for 1 hour with 1 % BSA in PBS- T. After blocking, plates were washed four
times with PBS-T and 150 ~l of culture supernatant was added to each well, typically
with three serial dilutions of each sample. For a standard curve, recombinant mouse IL-
for two hours at room temperature, and supernatants were washed out of the wells. Plates
was serially diluted from 500 to 7. pg/ml. Samples were allowed to bind the antibody
were washed six times with PBS-T and biotinylated rat anti-mouse IL-2 detection
antibody was added to each well (100 ~l/well) diluted 1:500 in 1% BSA PBS-T. After a
one hour incubation, plates were washed four times with PBS- T and 1 00 ~l HRP-
conjugated avidin (Vector Labs, #A-2004) diluted 1:2500 in 1% BSA PBS-T was added
to each well. The avidin was allowed to bind biotin for 30 minutes, and then the plates
were washed six times with PBS-T and twice with PBS. Following the washes, 100 ~l of
OPD buffer (0.05M Na HP04, 0.025M NaCitrate dihydrate, pH 5 , 1 mg/ml 0-
phenylenediamine (Sigma #P 1526), 2. ~l/ml Oz) was added to each well. Color was
permitted to develop over 5-30 minutes and 25 ~l of 3M HCl was added to each well to
stop the colorimetric reaction. Plates were read at 490 nm on a Molecular Devices eMax
plate reader.
Transgenic T Cell Adoptive Transfers
Spleens and inguinal, superficial and deep axilary, cervical, and mesenteric
lymph nodes were removed from DO 11. 1 0 OVA TCR transgenic mice into wash
medium, homogenized between frosted glass slides, and washed in wash medium. RBCs
were lysed by a five-minute incubation on ice in Gey s lysis solution, and cells were
washed three times in wash medium then resuspended at 133.33xl0 cells/ml of sterile
endotoxin-free PBS. It was determined by flow cytometry that approximately 15% of
splenocytes and lymphocytes were transgenic , as assessed by staining with the KJ126+
clonotypic antibody (Caltag, #MM7504). Thus, 500 ~l of cell suspension at a
concentration of 133.33xl0 cells/ml containing 10 KJ126+ cells was injected
intravenously into the recipient mouse. Recipients were age- and sex-matched, non-
irradiated BALB/c mice (syngeneic to the DOl1.10). One day following cell injections
recipients were given another intravenous injection consisting of 300 J.g OV A32_339
peptide solubilized in sterile, endotoxin- free PBS. Mice were left unmanipulated for 12
days following cell injections, at which point their spleens , inguinal lymph nodes
axilary lymph nodes, and cervical lymph nodes were removed, Gey's-treated, washed
twice in wash medium, and resuspended in growth medium. A cohort of cells was
stained with anti-CD4 , anti-DOl1.lO TCR (KJ126), and anti-PDl , and analyzed by flow
cytometry. Another cohort was rechallenged with irradiated syngeneic splenocytes as
described above, pulsed with increasing doses of OV A32-339. Cells were stimulated for
88 hours, the last 16 hours of which included 1 ~Ci of eH)-thymidine. The proliferative
response to antigen was normalized to the percentage of KJ126+ cells in the splenocytes
and lymphocytes of each recipient.
Tolerance Induction with DST and aCD154 monoclonal antibody
To prepare DST, spleens were removed from Balb/C mice and mashed between
glass slides in RPMI 1640 medium (without serum and antibiotics). Cells were fitered
through a 100-J.m sieve and washed twice in RPMI 1640. After the last wash, cells were
counted and diluted to 20x10 /ml in RMPI 1640. 500 ~l of cell suspension was
administered intravenously into C57BL/6 recipients , either alone or concurrently with
500 ~g of anti-CD 154 mAb (MRl) delivered intraperitoneally. Spleens were removed 3
or 7 days after transfusion and stained with APC-conjugated anti-CD4 (BD Pharmingen
#553051) and FITC-conjugated anti-PD- l (eBiosciences #11-9981-82) for analysis by
flow cytometry. The mice whose spleens were removed on day 7 were given an
additional dose of aCD154 on day 3 following DST.
- Chapter 3 -
Egr- , a Zinc-finger transcription factor, is highly expressed in anergic T cells, and
is required for full induction of anergy
Introduction to Chapter 3
It is well established that there exists a phenotypic distinction between T cell
clones receiving a signal through the TCR, and those receiving signals through both the
TCR and CD28 (72) (Figure 10). The first aim of this project, work done primarily by
John Harris , consisted of optimizing a system in which mRNA profies from untreated
anergized, or stimulated A.E7 T cell clones were compared using Affymetrix GeneChips.
Samples for analysis were prepared in biological triplicates from each of these
populations at three time points: immediately following the 12-hour antibody treatment
with aCD3 or aCD3+aCD28 (day 0), day 2 , and day 5 after removal from the antibody.
It was determined that day 5 was the earliest time at which anergized cells and stimulated
cells responded differently to antigenic rechallenge (145). Prior to this time, the cells
treated with aCD3 and aCD28 stimulation were hypo-responsive to antigen, similarly to
the anergic cells. Analysis of the data from these mRNA profiing experiments produced
a list of gene products more highly expressed in anergic cells than in either untreated
cells or productively stimulated cells. From these we chose Egr-2 as a potentially
important gene in the anergic phenotype.
Figure 10
20000
17500
a. 15000
'Q 12500
.- 
10000
7500
5000
2500
3 2.5 5.0 10.0 20.
uM Antigen (PCC)
Untreated
.. 
Anergic (TCR)
Stimulated (TCR+CD28)
Exogenous IL-2 Treatment
50000
40000
Q) 30000
20000
10000
Untreated Anergic Stimulated
. ,
Legend for Figure 
A. A.E7 CD4+ T cell clones stimulated through their TCR with immobilized
aCD3 antibody develop a phenotype of hypo-responsiveness to antigenic stimulation.
The addition of soluble aCD28 antibody to the stimulation culture prevents the cells from
developing this anergic phenotype. Cells were initially stimulated (aCD3 or
aCD3+aCD28) for 12- 16 hours, removed from the antibody, and left in cultue for at
least five days before rechallenging them with irradiated (3000 rad) syngeneic
splenocytes pulsed with increasing doses of pigeon cytochrome C. These two
populations are shown in reference to a previously untreated population. B. Anergized
A.E7 clones are equally as responsive as untreated or fully stimulated clones to
exogenous IL- , demonstrating that their capacity to proliferate in response to some
stimuli is not impaired.
j, '
Background of Egr-
Members of the Early Growth Response family of genes (Egr- 4) are induced
very rapidly following cell stimulation. A hallmark feature of the Egr family is a DNA
binding domain consisting of three zinc-finger motifs (146). This domain has been
demonstrated to bind the DNA sequence GCGGGGGCG, whose presence in gene
promoter regions has been shown to faciltate the transactivation of Egr family target
genes (147). Egr-2 has been studied most extensively in the nervous system, and its role
in the immune compartment has not been the focus of much study to date; its targeting in
knockout mice results in early lethality due to defects in hindbrain patterning, peripheral
nerve myelination, and bone formation (148). In T cells , it has been shown that Egr-2 up-
regulation is dependent on members of the NFAT family, and that Egr-2 may play arole
in the NFAT-dependent regulation of Fas ligand (147). Given the demonstrated
importance ofNFAT in T cell anergy (59), we attempted to furher characterize what role
Egr-2 may play in this phenotype.
, "
Egr-2 is up-regulated in anergic T cells relative to untreated and stimulated
populations
Given the relatively high number of mRNAs differentially expressed by anergic
cells, especially at the day 2 time-point, it was necessary to consider the known
characteristics of these gene products in order to prioritize them. It was our initial goal to
identify a primary point of regulation for anergy, and a transcription factor seemed likely
to be a good candidate. Our hypothesis was that a transcription factor active early in the
processes that distinguish anergy from stimulation could activate a network of genes
whose cumulative actions result in resistance to antigenic stimulation. As shown in
Figure l1A, Affymetrix GeneChips show that Egr-2 mRA is expressed to a greater
degree in anergic T cells than in either untreated or stimulated cells. These data were
confirmed by purifying total RNA from untreated, anergic , and stimulated cells, at the
same three time-points as were examined in the Affymetrix screen, synthesizing cDNA
from these, and RT-PCR amplifying a region of the Egr-2 message to confirm the
Affymetrix data. As shown in Figure IIB , elevated Egr-2 mRNA in anergic cells was
detected by RT-PCR. It is important to note that mRA levels are not an exact
representation of the protein profies of a given cell population, due to phenomena such
as differences in mRNA stability, post-transcriptional regulation, and post-translational
regulation. Thus, it was important to confirm these mRA data by assessing the levels of
Egr-2 protein in all three populations of interest.
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Egr-2 is up-regulated in anergic T cell populations. A. Affymetrix GeneChip
analysis shows Egr-2 to be up-regulated in anergic cells. B. RT -PCR confirms that Egr-
RNA is increased in anergic cells , compared with both untreated and fully stimulated
populations.
Western blotting for Egr-2 protein revealed that these mechanisms were not
significantly altering Egr-2 protein levels , since the relative band intensities of Egr-
protein reflect mRNA levels reasonably closely. As shown in Figure 12A, Egr-2 protein
is expressed at similar levels in both anergic and stimulated A.E7s at the earliest time-
point assessed (12 hours, or day 0). Over time, after removal from antibody, Egr-2 can
be seen to dissipate rapidly in the stimulated A.E7s, but persists in the anergic cells. Egr-
2 can be detected in anergic celllysates to day 9 , far longer than in stimulated samples.
Elevated levels of Egr-2 correlate with the anergic phenotype , as seen in Figure12B.
Egr-2 protein levels decrease in the presence of IL-2 concurrently with the reversal
of the anergic phenotype
An important characteristic of the anergic phenotype is that it is not permanent;
over time anergic cells retu to an antigen-responsive state. The addition of exogenous
IL-2 to the cultue medium reverses anergy quickly, supporting the hypothesis that IL-
receptor signaling prevents anergy in a costimulatory environment. Given the correlation
of Egr-2 expression and the anergic phenotype thus far, we sought to determine the effect
of exogenous IL-2 on Egr-2 protein expression. We considered the outcome important
because it was not clear from existing data whether the decrease in Egr-2 levels in
stimulated cells was due to the same signaling events leading to IL-2 production, a
process impaired in anergic cells , or the result of IL-2 receptor signaling, which anergic
cells are capable of transducing
Figure 12
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A. Egr-2 protein expression is high in anergic and stimulated populations at early
times, but is rapidly down-regulated in stimulated populations , while expression persists
in anergic populations. B. The degree of hypo-responsiveness correlates with the level
of Egr-2 expressed as can be seen when cells are rechallenged at day 9. The anergic
cells, which are stil expressing Egr-2 protein, are unresponsive to antigenic rechallenge
while the stimulated cells, which have down-regulated Egr- , respond well. Western blot
and eH)-thymidine plot couresy of John Harris.
As seen in Figure 13 , the addition of exogenous IL-2 to anergic cultures following
their removal from the anergizing stimulus results in a rapid decrease in Egr-2 protein
levels. This suggests a direct relationship between the presence of Egr-2 protein and the
persistence of the anergic phenotype. Importantly, following 10 days of rest, the anergic
cells treated with exogenous IL-2 were markedly more responsive to antigenic
stimulation, demonstrating a reversal of anergy.
Depletion of Egr-2 with siRNA partially restores antigenic responsiveness
and IL-2 production in early stages of anergy
Given the natue of Egr-2 as a transcription factor, we hypothesized that Egr-
might playa role in inducing some of the early biochemical changes required to prevent
IL-2 production. To test this, we employed RNA interference , a means of degrading
mRNA first characterized in Caenorhabditis elegans (149) and optimized extensively in
mammalian systems (150). The value of being able to modulate protein levels without
changing the natue of the signals received by the lymphocytes lies in its specificity. To
establish a causative relationship between Egr-2 protein expression and the anergy
phenotype, we sought to reduce Egr-2 protein levels during anergy induction. 22-mer
siRNA duplexes corresponding to the Egr-2 mRNA sequence were transfected into A.
T cells by electroporation, after which the cells were allowed to recover in medium at
C for 4-6 hours, and anergized as described in Materials and Methods. Using a
fluorescent-tagged non-specific siRNA duplex, it was determined by flow
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Legend for Figure 13
A. Egr-2 protein levels decrease in the presence of exogenous IL- , concurrently with the
reversal of the anergic phenotype. Levels of Egr-2 protein were assessed in untreated and
anergic samples by Western blotting. Cells were processed immediately after removal
from stimulus, and 1 , 3, 5 , 7 and 10 days thereafter, either in medium or in medium
supplemented with 10 U/ml exogenous IL-2 to induce proliferation. B. Ten days after
removal from the anergizing stimulus cells were rechallenged with syngeneic
splenocytes pulsed with increasing doses of pigeon cytochrome C. Western Blot and
eH)-thymidine plot courtesy of John Harris.
cytometry that electroporation was 90-99% effective in delivering duplexes to the cell
cytoplasm. Fluorescence microscopy was used to confirm that siRNA was internal to the
cell and not sticking to the cell membrane (Figure 14). Five days following the induction
of anergy, Egr-2 levels in the siRNA transfected cells were detectably lower than those in
non-transfected anergic cells, or anergic cells transfected with a non-specific siRNA
(Figure 15). The use of the non-specific siRNA demonstrated that the presence 
double stranded RNA in the cell did not change Egr-2 levels. Upon antigenic rechallenge
anergic cells in which Egr-2 had been knocked down showed an increase in
responsiveness, in some cases responding similarly to the previously untreated
population. These data show that the presence of Egr-2 is crucial to some aspect of the
anergic phenotype, at least with regard to anergy induction.
Since the primary barrier to proliferation in anergic cells is the inability 
produce IL- , we asked whether the restored ability of Egr- depleted anergic cells to
respond to antigenic stimulation was a result of their ability to make IL-2. To see what
effect Egr-2 depletion has on this signaling block, Egr-2 siRNA-treated anergic cells
were stimulated with immobilized aCD3 antibody and soluble aCD28 antibody for 16
hours, at which point the culture medium was removed and stored at - For
comparison, a previously untreated population of A.E7 cells , an anergic population not
transfected with siRNA, and an anergic population transfected with a non-specific
siRNA, were stimulated in the same manner.
Figure 14
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Legend for Figure 14
Electroporation of A.E7 T cells is a highly effcient means of transfecting siRNA.
A. The introduction of FITC-conjugated siRNA duplexes with a voltage of 310 V at 950
J.F results in a small amount of cell toxicity. B. Flow cytometry analysis of FITC+ cells
determined that over 95% of cells were successfully tranfected by this method. C-F. It
was determined by fluorescence microscopy that the siRNA was delivered to the
cytoplasm of the cells , rather than simply sticking to the outer cell membrane. C and E
are brightfield images corresponding to the fluorescence images D and F, respectively
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Knocking down Egr- protein levels with siRNA restores antigenic
responsiveness of anergic cells. A. Anergic cell populations were transfected with two
distinct Egr-2 siRNAs , anergized with aCD3 antibody, and rested for five days. After
the rest period, significantly less Egr-2 protein could be detected in those cells treated
with Egr-2 siRNA, whereas Egr-2 levels were unchanged in cells transfected with a non-
specific siRNA. All anergic populations expressed more Egr-2 protein than a previously
untreated control population. B. Upon antigenic rechallenge, anergic A.E7 cells treated
with Egr-2 siRNA display a greater specific response to pigeon cytochrome C than do
anergic cells transfected with a non-specific siRNA or those not transfected. This was
consistent across two different siRNAs targeting Egr- , and the antigenic responsiveness
of the cells was proportional to the effcacy of the siRNA in knocking down protein
levels.
The IL-2 protein levels from the supernatants collected from these stimulation
cultures were measured by sandwich ELISA. As shown in Figure 16, the Egr-2 siRNA-
treated anergic cells are capable of making more IL-2 upon antibody stimulation than are
untransfected anergic cells and those transfected with control siRNA.
Egr-2 depletion in anergic cells restores ERK activation upon stimulation
As mentioned previously, anergic cells are defective in their ability to
phosphorylate ERK MAP kinases (87), and it has been proposed that this defect is at least
partially responsible for an anergic cell' s inability to make mitogenic doses ofIL-2. In an
attempt to describe the mechanisms by which Egr- depleted anergic cells produce IL-
the phosphorylation status of ERK kinases was examined. To assess for ERK activation
status , A.E7 cells were transfected with Egr-2 siRNA or non-specific siRNA, or were left
untransfected, rested in medium for 4-6 hours, and anergized. After removal from the
anergizing stimulus, cells were rested in medium for five days, purified over a
Lympholyte M gradient, and stimulated for 1 hour with immobilized aCD3 antibody and
soluble aCD28 antibody. After 1 hour, cells were removed from the antibody, washed in
cold PBS , and lysed in SDS buffer. The levels of total ERK and phospho-ERK were
assessed by Western blotting (Figure 17). As shown, levels of total ERK do not change
across the different conditions, and in the absence of subsequent stimulation, there is no
active ERK present after five days of rest.
After one hour of stimulation, ERK MAP kinases were activated in the previously
untreated sample and mostly inactive in the untransfected and control siRNA-transfected
Figure 16
siRNA: None
Resting
None Con
Anergized
r2- 1
Resting Anergized
Egr-2.-
actin.
siRNA: None None Con Egr2- 1
Legend for Figure 16
Egr-2 depletion in anergic cells restores their ability to produce IL-2 upon full
stimulation. Anergic A.E7 T cells were transfected with siRNA targeting Egr-2 mRNA
a non-specific siRNA, or no siRNA. Four-to-six hours after transfection, cells were
anergized and permitted to rest in medium for 5 days. After resting, a subpopulation of
cells of each condition was restimulated for 16 hours with platebound aCD3 antibody
and soluble aCD28 antibody, after which the culture supernatants were collected and IL-
2 was measured by sandwich ELISA. IL-2 quantities were determined relative to a
standard curve of increasing doses of recombinant mouse IL-
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Legend for Figure 17
Egr-2 knockdown in anergic T cells restores ERK phosphorylation upon
rechallenge. Anergic cells treated with no siRNA, a non-specific siRNA, or an siRNA
specific to Egr- , or previously untreated cells, were rested five days following the
anergizing stimulus and rechallenged with aCD3 and aCD28 antibodies. Cells were
removed from antibody by scraping after one hour, washed in cold PBS , and lysed in
SDS buffer. The levels of total ERK and phospho- ERK expression were assessed by
Western blotting.
anergic samples , but there was a detectable increase in ERK phosphorylation when the
anergic cells were treated with Egr-2 siRNA. These data suggest that the presence of Egr-
2 in anergic cells is somehow able to prevent ERK phosphorylation.
Egr-2 depletion prevents anergy induction, but does not reverse established anergy
Having seen that high Egr-2 protein levels correlate with the presence of the
anergic phenotype, we sought to examine more closely the kinetics of Egr-2 activity. It is
possible that the establishment of anergy occurs over numerous phases. The data
presented thus far show the importance of Egr-2 in the induction of anergy, but the
question remains as to the role of Egr-2 after anergy has been established. No study has
yet described a factor active during the maintenance phase of anergy.
To assess whether the dampening role of Egr-2 persists throughout the course of
the anergic phenotype, A.E7 cells were anergized with immobilized aCD3 antibody,
rested for five days, and transfected with Egr-2 siRNA duplexes. Following transfection
the cells were rested in medium for two additional days to allow the siRNA to effectively
direct the degradation of the Egr-2 message. At this point the cells were rechallenged
with irradiated syngeneic splenocytes pulsed with pigeon cytochrome C. Surprisingly,
knocking down Egr- after anergy was established did not restore antigenic
responsiveness (Figure 18). In fact there was no detectable difference in antigenic
responsiveness between the Egr-2 depleted anergic cells and the control populations. The
absence of restored proliferation at this time-point was corroborated by the inability of
Figure 18
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Legend for Figure 18
Egr-2 knockdown does not restore antigenic responsiveness in anergic cells after
anergy has been induced. A.E7 cells were anergized with immobilized aCD3 antibody,
rested for five days after removal from the anergizing stimulus , and transfected with
siRNA targeting Egr-2 mRNA. A. Cells were rested for two additional days and
rechallenged with irradiated syngeneic splenocytes pulsed with pigeon cytochrome C for
48 hours. After 48 hours , 1 f.Ci of eH)-thymidine was added to each well and cells were
incubated at 37 C for 16 hours, at which point they were harvested and read. B. IL-
production was measured by stimulating Egr-2 knockdown anergic cells for 16 hours
with immobilized aCD3 antibody and soluble aCD28 antibody, alongside anergic cells
not treated with siRNA and those treated with a non-specific siRNA. Culture
supernatants were coll cted after 16 hours and IL-2 production was measured by captue
ELISA. C. A subpopulation of cells was lysed at this point for assessment of Egr-
protein levels by Western blotting.
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the Egr-2 siRNA-treated cells to produce IL-2 upon antibody stimulation, in contrast to
those cells treated prior to anergy induction.
Discussion of Chapter 3
Anergy is very likely a complex process involving a number of genes that serve to
mediate the resistance to costimulation. The data presented in this chapter show that the
transcription factor Egr-2 functions in establishing the anergic state in A.E7 T cells. The
expression profie of Egr-2 is consistent with the characteristics of a factor that confers
anergy as predicted by Powell et al. (82) in that 1) it is initially up-regulated in both
anergized and fully activated T cells before their proliferation and its expression 
prevented by cyc1osporine A (75); 2) its expression decreases more rapidly in
proliferating cells than in anergized cells; and 3) high expression levels of Egr-2 in
anergy are decreased by exposure to IL- , which concurrently reverses the anergic state.
Interestingly, high expression of Egr-2 has been found in other studies to be associated
with anergy. Lechner, et. al. screened for genes expressed in primary T cells anergized in
vivo , and reported the induction of Egr-2 expression in the anergized T cell population
(151), but these initial findings were not expanded.
Over time there is a reversal of anergy in the A.E7 cells coincident with a loss of
Egr-2 expression. It is possible that Egr-2 transactivates other anergy factors, and that the
loss of Egr-2 expression contributes to the transient natue of anergy over the long term.
As it was not possible to reverse anergy by depleting Egr-2 five days after anergy
induction, it is possible that key transcriptional targets of Egr-2 are present by this time
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and are not down-regulated quickly enough to restore normal responsiveness in our
experiments. It is possible that knocking down Egr-2 during anergy maintenance and
waiting longer than two days to allow for the down-regulation of Egr-2 targets would
restore responsiveness to the anergic cells.
Egr-2 may be responsible for activating a network of genes whose proteins
mediate the many different aspects of the anergic phenotype, including hypo-
responsiveness, differential homing, and cytokine production. Identifying the factors
under the regulation of Egr-2 wil provide important insight into the mechanisms
involved in the maintenance of immune tolerance.
104
- Chapter 4-
PD- , a negative costimulatory receptor, has an essential role in
maintaining CD4 clonal anergy
Chapter 4 Introduction
The two-signal model of lymphocyte activation was first proposed by Bretscher
and Cohn in 1970 (152). They showed that recognition of one determinant on an antigen
resulted in paralysis of antibody production, whereas recognition of two determinants
resulted in induction of antibody synthesis by B cells. It is well agreed that a similar
paradigm applies to T cell signaling: a signal through the TCR results in tolerance
whereas a signal through the TCR combined with a signal through a costimulatory
receptor results in expansion (78). Early studies determined that a signal through CD28
on the T cell surface would rescue the cell from tolerance, but it has been shown over
time that the process of co stimulation is much more complicated than this. A number of
family members have been added to what has come to be known as the CD28
superfamily of receptors, and a number of B7 family members have been found to act as
their ligands. The concept of co stimulation has evolved from simply the presence or
absence of an activating signal, to include the comprehensive balance of positive
co stimulatory signals, such as that through CD28 , and negative costimulatory signals, the
prototype of which is CTLA- (153). Another co stimulatory receptor/ligand
combination, CD40/CD 154, has been shown to facilitate the rejection of allografts since
blocking the interaction of these cell surface proteins in combination with DST enables
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engraftment of allografts (26). The mechanisms of these processes are currently under
investigation.
One of the negative co stimulatory pathways has emerged recently as a topic 
high interest. This receptor-ligand combination, PD1-PDLl/2 (B7-Hl/B7-DC), seems to
be important to peripheral tolerance, since knocking it out results in strain-specific
autoimmune disorders, and studies have also shown its engagement can promote allograft
survival (154). The data presented in this chapter demonstrate the importance of PD- 1 in
the maintenance of T cell anergy.
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PD-1 knockdown at late time-points results in the reversal of T cell anergy
In the previous chapter it was demonstrated that depleting Egr-2 after anergy has
been established has no effect (145). On the basis of the Affymetrix GeneChip array
data, a number of genes shown to be up-regulated at the day 5 time-point were chosen as
potential anergy maintenance factors. siRNA technology was again employed to
determine the effects of depleting these genes. The list of the genes selected for
investigation can be found in Table A.E7 cells were anergized or co stimulated
removed from antibody, and rested in medium for five days. At this point, anergic cells
were transfected with pools of four distinct siRNA duplexes (available commercially as a
SMARTPool from Dharmacon) and rested for an additional two days in growth medium
to allow the siRNA to effectively direct the degradation of the mRA. After two days in
medium, live cells were purified over a Lympholyte M gradient and restimulated with
APCs pulsed with pigeon cytochrome C.
Surprisingly, depletion of many of the chosen candidates did not reverse the
anergic phenotype. It has long been speculated that anergy is a complex network of
differential gene expression and enzymatic activities, but despite this only one candidate
exhibited a functional role in this assay. As shown in Figure 19 , only PD- 1 appears to
contribute to anergy maintenance.
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Legend for Table 1: Genes highly expressed five days after anergy induction.
Figure 19
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Legend for Figure 19
Genes found to be differentially expressed in anergic A.E7 T cells were silenced
with siRNA SMARTPools five days after anergy induction. Cells were then rechallenged
with antigen-pulsed APCs to assess their antigenic responsiveness. Egr-2 was included
to establish experimental continuity with our previous studies demonstrating the absence
of a role for Egr-2 at late time-points. Of those selected for examination, only PD-
knockdown restores the responsiveness of anergic cells, suggesting an important role for
PD- 1 in anergy maintenance. Though SMARTPools are guaranteed by Dharmacon, Inc.
to effectively silence their target genes, it would be necessary to assess the protein levels
of each population tested in order to confirm that the populations other than PD- 1 in fact
do not contribute to anergy maintenance.
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PD-1 mRNA and protein levels are increased in anergic cells
To confirm that PD- mRA is expressed at higher levels in anergic cells than in
untreated or stimulated populations, total RNA was purified from these three populations
five days after anergy induction. cDNA was synthesized from the total RNA 
described in Materials and Methods and a region of PD- 1 message was amplified by RT-
PCR. As shown in Figure 20, the levels ofPD- 1 in these three populations shown by RT-
PCR reflect those shown by the GeneChips. To rule out alterations in PD- 1 expression
by post-transcriptional and post-translational regulatory mechanisms, PD- 1 levels were
assessed in SDS lysates of untreated, anergic , and stimulated cells, in which PD- 1 protein
levels were determined to be up-regulated in the anergic populations.
PD-1 siRNA increases antigenic responsiveness in anergic A.E7 cells, but not in
untreated or fully stimulated populations.
A notable idiosyncrasy of the A.E7 T cell model is the variable degree to which
the cells respond to CD28 costimulation. The population of co stimulated cells shows
some evidence of anergy, in that they do not respond well to rechallenge with lower
doses of antigen (as seen in Figure 10). In contrast, these same cells often respond as
well as previously untreated cells to higher doses of antigen. This characteristic
introduces a small amount of ambiguity when attempts are made to define distinctions
between anergic and responsive cells.
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Legend for Figure 20
PD- 1 is highly expressed in anergic A.E7 cells five days after anergy induction.
A. Affymetrix GeneChips show PD- mRA to be increased in anergic cells (A)
compared to previously untreated (D) and fully stimulated (S) cells. B. This increased
PD- 1 expression is confirmed by RT -PCR of samples purified five days after anergy
induction. C. PD- 1 protein is highly expressed in anergic cells five days after anergy
induction.
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For example, Egr-2 plays a role in dampening the response to antigenic
rechallenge in fully stimulated cells as well as anergic cells (Figure 21). To determine if
PD-1 also dampens the ability of costimulated cells to respond fully to antigenic
rechallenge, PD- 1 siRNA was transfected into untreated, anergic, and stimulated A.
cells. In contrast to the data showing the dampening effect of Egr-2 in stimulated cells
there does not appear to be a similar impact of PD- 1 depletion on stimulated cells:
knocking down PD- 1 in stimulated populations or previously untreated populations of
E7 cells does not appear to alter their antigenic responsiveness, despite low but
detectable levels of PD- 1 protein in both populations. This is shown in Figure 22.
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Legend for Figure 21
Despite our use of anergic and costimulated A.E7 cells as phenotypically
disparate populations, the costimulated cells do not respond as well as previously
untreated cells to antigenic rechallenge. This has led some to propose that the
costimulated cells are partially anergic. Egr-2 protein levels can stil be detected in
stimulated A.E7s by Western blotting, and these cells show an increase in their antigenic
responsiveness when Egr-2 is depleted with siRNA.
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Legend for Figure 22
The ability of PD- 1 to suppress proliferation is specific to anergic populations. A.
PD- 1 depletion with siRNA results in increased proliferation in anergic (A) cells, but not
in a previously untreated (D) or costimulated (S) population of A.E7 cells. Cells were
anergized or stimulated, rested for 5 days, transfected with PD- 1 siRNA, rested for an
additional 2 days, and rechallenged with irradiated APCs pulsed with cytochrome C.
eH)-thymidine data are presented as a fold-increase of PD-1 siRNA-treated cells
thymidine incorporation compared to control siRNA-treated cells thymidine
incorporation. B. As shown by Western blotting, small amounts of PD- 1 protein can be
detected in previously untreated and costimulated A.E7 cell populations, but siRNA-
mediated PD- 1 depletion does not affect their response to antigenic challenge.
II'
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PD-1 depletion restores anergic cell responsiveness in an IL- dependent fashion
PD- 1 engagement on T cell blasts has been shown to inhibit IL-2 production
(155). To determine if IL-2 levels change subject to the modulation of PD-1 protein
levels , anergized cells were transfected with control siRNA or PD- 1 siRNA, rested in
media for two days , and rechallenged with aCD3 and aCD28 antibody for 16 hours, at
which point the supernatants were collected and assayed for IL-2 cytokine by IL-
capture ELISA. Surprisingly, as shown in Figure 23A, knocking down PD- 1 in anergic
cells does not appear to restore their ability to make IL- Since the restored
responsiveness seen by eH)-thymidine incorporation was the result of APC stimulation
and not antibody stimulation, this experiment was repeated by stimulating the cells with
irradiated syngeneic splenocytes pulsed with cytochrome C rather than aCD3 and
aCD28 antibodies. Again, that there was not a significant change in IL-2 production
(shown in Figure 23B). It is possible that the kinetics of IL-2 production change in this
case, and the sixteen-hour time-point is not ideal as was the case in the Egr-2 study. It is
also possible that another cytokine is acting in the place of IL- , prompting the PD-
depleted anergic cells to proliferate. A third possibility is that the PD- 1 knockdown cells
are consuming IL-2 quickly enough that there is no excess in the supernatant, giving the
appearance that they are making equal amounts to the anergic populations.
ji1!
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Legend for Figure 23
Depletion of PD- 1 does not permit increased IL-2 production upon rechallenge
either with A. aCD3 + aCD28 antibody or with B. APCs. AE7 cells were anergized
rested for 5 days, and transfected with control siRA or siRNA targeting PD-1. The
cells were then rested for an additional 2 days and rechallenged for 16 hours with either
anti-CD3 + anti-CD28 antibody, or cytochrome C-pulsed APCs. Supernatants were
collected 16 hours later and assayed for IL-2levels by IL-2 capture ELISA.
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In an attempt to consider the question from another angle, a neutralizing aIL-
antibody (Pharmingen Clone S4B6 , #554375) was added to the restimulation culture at a
concentration of 10 f.g/ml. An equal concentration of rat IgG2a antibody was used as a
control. If another cytokine is responsible for the restorative effect of PD- 1 depletion
then neutralizing IL-2 should not affect the PD-1 siRNA-treated cells' ability to
proliferate in response to antigenic stimulation. As shown in Figure 24, the restored
antigenic responsiveness in the PD-1 siRNA-treated anergic cells is IL-2 dependent.
Although increased levels of IL-2 production cannot be detected in cells treated with PD-
1 siRNA, blocking IL- signaling nonetheless prevents the restoration of antigenic
responsiveness. This rules out the possibility that another cytokine is acting in place of
IL-2 to drive the proliferation of these cells.
Adoptively transferred transgenic T cells tolerized with intravenous peptide up-
regulate PD-
Adoptively transferred transgenic T cells can be tolerized in vivo by injecting the
recipient with soluble peptide intravenously. These cells exhibit a hypo-responsiveness
to antigenic stimulation similar to that of anergized A.E7 cells (72). This model is well
accepted as a model of anergy in vivo (112).
Experiments were performed to confirm that ex vivo the adoptively transferred
transgenic cells were indeed hyporesponsive to their cognate antigen. It was first
determined that 66. 67x10 total lymphocytes and splenocytes need to be injected to
achieve a transfer of 1 0 OVA-specific T cells. This allowed for the detection of a small
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Legend for Figure 24
PD- 1 depletion restores antigenic responsiveness in an IL- dependent manner.
Cells were anergized or stimulated, rested for five days, and a subpopulation of anergic
cells was transfected with PD- 1 siRNA. Cells were rested for an additional two days and
rechallenged with irradiated syngeneic splenocytes pulsed with increasing doses of
cytochrome C. The PD- 1 siRNA-treated anergic cells were divided into two populations
and their culture medium was supplemented with either 10 f.g/ml of rat IgG2a antibody,
or 10 f.g/ml anti-IL-2 antibody. Cells were challenged for 64 hours; after 48 hours, 1 f.Ci
of eH)-thymidine was added to each well.
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population of circulating cells at later times. Eleven days following cell transfusion
spleens and lymph nodes were harvested, a single cell suspension was made , and these
cells were rechallenged with antigen-pulsed, irradiated syngeneic splenocytes to assess
their proliferative capability. As seen in Figure 25 , a significant increase in PD-
expressing transgenic cells correlates with the tolerized phenotype.
PD-1 expression in the DST + ClCD154 tolerance induction protocol
It has been proposed that anergy is one mechanism of peripheral tolerance, and
there are studies that have proposed evidence for the importance of anergy in allograft
transplantation (156- 164). The data presented above suggest that PD- l may be expressed
specifically on anergic cells, and thus may act as a cell surface marker for
hyporesponsive cells. One study has suggested a role for PD- 1 in prolonging allograft
survival (154). If an anergic cell population actively contributes to the peripheral
tolerance induced by DST and aCD154 treatment, then it is possible that PD-
expression would be increased on a select population of CD4+ cells in tolerized mice. To
test this possibility, C57BL/6 (H2 ) mice were transfused with BALB/c (H2 ) splenocytes
to serve as a general source of alloantigen. Half of the mice were given 500 f.g of
aCD l54 mAb , which serves to block T cell costimulation. After 3 and 7 days , spleens
were removed and homogenized to a single cell suspension, and the RBCs were lysed
with Gey s solution. Total cells were then stained for CD4 and PD- , and CD4+ cells
were analyzed for PD- 1 expression. It would not be surprising if a difference
Figure 25
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Legend for Figure 25
PD- l expression increases in CD4+ T cells tolerized in vivo. A. DO ll. 1 0 OVA
transgenic CD4+ T cells were adoptively transferred into BALB/c recipients and
tolerized 24 hours later with an intravenous injection of 300 f.g of OVA peptide. As a
control, transgenic cells were injected without the tolerizing peptide injection. Eleven
days after adoptive transfer, lymph node and spleen cells were taken from the mice and
rechallenged with irradiated BALB/c splenocytes pulsed with OVA peptide.
Interestingly, the peptide-induced tolerance can by reversed by including 15 U/ml rmL-
in the restimulation culture , in addition to the 4 ug/ml OVA peptide. B. A population of
cells was also stained for PD- l and the clonotypic T cell receptor, showing that cells
tolerized in vivo up-regulate PD-
! '
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between the groups was undetectable , since the percentage of total CD4+ cells responding
to alloantigen is likely small , but as seen in Figure 26 , there is a significant increase in
PD- l expression on the CD4+ population from the mice that received DST only.
Interestingly, there is significantly less PD- l expression in the mice given DST and
treated with aCD154 mAb.
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Legend for Figure 26
Treatment with aCD154 mAb down-regulates PD-l in DST-treated mIce.
C57BL/6 mice were transfused with 10 BALB/c splenocytes in RMPI 1640. Half of
these were concurrently given an intraperitoneal injection of 500 f.g of aCD 154 mAb
(MRl). As a control , a group of C57BL/6 mice were not injected with cells or antibody.
Spleens were removed on day 3 or 7 and stained for CD4 and PD- l. The mice whose
spleens were examined on day 7 were given another injection of aCD154 on day 3.
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Chaper 4 Discussion
Programmed Death- l was named as the result of its appearance in a subtractive
hybridization screen comparing T cells undergoing apoptosis with live T cells (66). Later
studies from the same group detected increased PD- l expression on mouse thymocytes
and splenocytes stimulated with aCD3 or concanavalin A, and on spleen B cells
stimulated with anti-IgM antibody (165). Subsequent studies in human Jurkat T cells
confirmed this up-regulation by stimulation with TP A, and showed that maximal
expression took place at 48 hours. This study also definitively showed that PD- l is
expressed on activated cells and not on cells undergoing apoptosis (166). Since PD- l is a
member of the immunoglobulin superfamily, it was first speculated that it might playa
role in T cell activation, but when the gene was targeted in the C57BL/6 mouse strain the
result was autoimmunity rather than lymphopenia (167). This phenotype was an
indication that PD- l may playa role in maintaining peripheral tolerance. Since the amino
acid sequence of PD- l contains a transmembrane region and PD- l is a member of the
CD28 superfamily, the natural question that arises is, to what ligands does PD- l bind?
PD- l does not contain the MYPPPY motif necessary for binding to B7- l and B7-2 (168).
This distinguishes it from both CD28 and CTLA- , who bind these two B7 family
members in order to carr out their respective functions. Since PD- l and CTLA-4 share a
23% identity, investigators examined other B7 family members in attempts to identify
ligands for PD- l (169). The result of these studies was the discovery of a novel B7 family
member, B7-Hl (PD-Ll), shown to specifically bind PD- l-expressing CHO cells. These
studies also examined the expression ofPD- , B7- , and B7-2 on APCs , and found that
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PD- l is not expressed by unstimulated monocytes, but is rapidly up-regulated when the
cells are stimulated, such as with IFN -"I. This up-regulation displayed very similar
kinetics to B7- l expression on monocytes. When the authors examined PD-
expression on dendritic cells, they found PD- L 1 expression increased dramatically over
16-20 hours after stimulation with LPS and IFN-
Using a PD- L l.Ig fusion protein, the authors of these studies extended their
findings to examine the effect of PD- l:PD-LI interaction on T cell stimulation
comparing wild-type mice with PD- l knockout mice. Adding PD-Ll.Ig to the stimulating
culture inhibited wild type T cell proliferation in a dose-dependent manner. This was not
the case with the PDl-/- T cells, which did not show a different response between aCD3
stimulation and aCD3 + PD- L 1.g stimulation. Interestingly, PD- l engagement by PD-
LIon APCs prevented IFN-y and IL- lO production by purified CD4+ T cells, suggesting
that PD- l plays an inhibitory role in both Thl and Th2 subsets. To characterize this anti-
proliferative effect furher, cells were stimulated with aCD3 , aCD28 , and PD-L1.g in
different combinations. These experiments showed that strong signaling through CD28 is
able to override the effect ofPD-L1.g on T cell stimulation.
Shortly following these studies, another ligand for PD-l was discovered and
named PD-L2 (B7-DC) (170). Studying these ligands together, the authors found that
ligation of PD- l on T cells arrested them in GO phase, but did result in cell death.
Interestingly, the authors also showed that ligation of PDl and TCR resulted in rapid
phosphorylation of SHP- , suggesting that increased phosphatase activity is a possible
mechanism by which PD- l exerts its anti-proliferative effects.
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PD-1 and Peripheral Tolerance
number of studies have implicated PD- l in peripheral tolerance. The
expression of PD- l has been detected on a greater variety of cell types than that of
CTLA-4. It has been speculated that PD- l may be acting in concert with CTLA-4 to
globally suppress unsolicited immune reactions (171).
Studies in cardiac allografts have suggested a possible role for PD- l in regulating
peripheral tolerance. In a fully-MHC-mismatched cardiac graft, PD- , PD- , and PD-
L2 can be seen to be up-regulated between days 2 and 5 with their expression remaining
high until end-stage rejection (172). This was not the case with isografts. These
experiments utilized total RNA isolated from heterotopic cardiac grafts, and therefore it
is not known which cell populations were specifically expressing these transcripts.
Interestingly, the use of aCD154 mAb therapy, with or without concomitant DST
decreased the intra-graft mRNA expression of PD-l and PD- , and significantly
decreased the expression of PD-Ll. This result is somewhat counterintuitive , given that
this therapy is known to prolong graft survival by inhibiting the immune response, which
is presumably also what PD- l does. Heart transplant recipients treated with cyclosporine
A or rapamycin to prolong engraftment also showed decreased expression of PD- , PD-
, and PD-L2. In order to furher dissect the role of PD- l in allograft tolerance, the
authors employed PD- L l.Ig fusion protein in combination with CSA or RPM to attempt
to prolong graft survival and found that PD-Ll.g + rapamycin therapy enabled long-term
engraftment. These studies demonstrate that the modulation of PD- l signaling may be
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utilized in other models of transplantation to establish or maintain a state of peripheral
tolerance.
The role of PD- l has been examined in other models of transplantation. In islet
transplantation experiments stimulating PD- with PD-Ll.g while blocking
costimulation with aCD154 mAb prolonged the survival of islet allografts (154). Neither
agent used alone extended survival significantly. In parallel studies, the authors
stimulated splenocytes with aCD3 ex vivo and found that low doses of PD-Ll.g and
aCD154 antibody completely abolished T cell proliferation. In contrast to the previously
discussed study, these findings suggest that it may be possible to exploit the combination
of PD- l signaling and costimulation blockade with aCD154 antibody to facilitate
allograft tolerance over the long term.
PD- l has been shown to playa role in the development of autoimmune diabetes in
the NOD diabetic mouse model (173). The use of blocking antibodies against PD- l and
PD-Ll rapidly precipitated diabetes in lO-week-old female NOD mice, whereas antibody
against PD-L2 had no effect. In 4-week-old mice, aPD-LI antibody induces diabetes in
mice 20 days following the initiation of treatment, while PD- l antibody has a less
profound effect, precipitating diabetes in just over a third of mice tested at this age.
Again, PD-L2 blocking antibody had no effect in this case. Despite the fact that few
male NOD mice develop overt diabetes at 10 weeks of age, blocking PD- PD-
interaction had a similar effect to that seen in females of this age: PD-Ll antibody
precipitated diabetes in 100% of the male mice treated, and PD- l antibody did so in 80%.
Again, PD-L2 antibody had no effect. Interestingly, at 4 weeks of age, PD- l antibody
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had no effect, whereas PD-Ll antibody induced diabetes in 75% of treated mice.
Hopefully future studies wil clarify this seeming discrepancy. It has been shown 
tumor models that PD-Ll may drive T cell apoptosis through a receptor other than PD-
(174), which may explain the greater activity of the PD-Ll blocking antibody than that
of anti-PD- l in these experiments.
Mechanisms of PD-1 signaling
The full details of what signals PD- l is delivering to the cell are not known, but a
number of studies have revealed important clues as to how PD- l may dampen a T cell
response. Ligation of PD-l on T cells has been shown to decrease IL-2 production in
response to stimulation with aCD3 antibody and PD-L1.Fc conjugated beads (175).
Stimulation with aCD3 antibody + PD-L1.Fc-conjugated beads also resulted in fewer
cellular divisions than aCD3-bound beads alone. Interestingly, when CD28 was added to
these stimulation cultures, suffcient IL-2 was produced to drive cell proliferation
suggesting a capability of CD28 to override negative signals delivered by PD- l in some
contexts. These data suggest that CD28 and PD- l signals are balanced against each other
when T cells are stimulated; when a strong PD- l signal is delivered, IL-2 production is
inhibited and the cell is incapable of proliferation. When CD28 signals are present in
suffcient strength, they override the negative signal delivered by PD- l and are able to
drive clonal expansion.
PD- l has no secondary or tertiary structural features suggesting it has any
inherent enzmatic activity that might be acting to directly inibit TCR signaling.
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Rather, there are two tyrosines whose surrounding residues classify them as 
immunoreceptor tyrosine inhibitory motif (ITIM) and an immunoreceptor tyrosine switch
motif (ITSM). These domains are known to bind phosphatases such as SHP- l and SHP-
(176), which are believed to mediate the negative regulatory functions for the receptors
they bind. In a series of studies demonstrating the importance of these domains in PD-
signaling, the cytoplasmic tail of PD- l was mutated at each of the domains to inactivate
them. The studies found that while mutation of the ITIM had no effect on the ability of
PD- l to inhibit IL-2 production, mutation of the ITSM completely abrogated the ability
of PD- l to dampen IL-2 production and proliferation (177). These studies also showed
interestingly, that SHP-2 binds the cytoplasmic tail of PD- l upon TCR stimulation, even
in the absence of any interaction between PD- l and its ligands , but the ability of PD- l to
inhibit cellular proliferation is dependent on receptor ligation. This rules out reasonably
well the possibility that PD- l is able to act in a ligand-independent manner, such as has
been shown with CTLA-4 (63).
Studies have investigated the relationship between other costimulatory pathways
and PD-l. Purified CD4+ T cells stimulated by aCD3 antibody and ICOS-ligand.Fc-
coated beads proliferate more vigorously than those stimulated with anti-CD3-coated
beads alone. The addition of PD-L1.Fc to the stimulation beads abrogates this effect.
This suggests that co stimulation through ICOS does not produce enough IL-2 to override
the negative signals delivered through PD- l (178). These studies show that exogenous
IL-2 can rescue CD4+ T cells from PD- l-mediated inhibition, and they also found that
exogenous IL-7 and IL- 15 are able restore T cell proliferation, possibly through their
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activity at the Yc subunit of the IL-2 receptor. Interestingly, IL-4 and IL- , which also
deliver signals through Yc cannot overcome PD- l-mediated inhibition. The authors
attempt to reconcile this distinction by speculating that it is the activation of ST AT5
which IL- , IL- , and IL- 15 are known to do (179), that enables the cell to overcome PD-
1 signals , whereas IL-4 and IL-21 act predominantly through other members of the STAT
family.
Attempts to define the biochemical mechanisms of PD- l signaling examined a
number of enzymes known to be necessary for productive T cell signaling. One study
showed that ERK and PKC- phosphorylation are impaired upon PD- l ligation
suggesting the intervention of PD- l in two important branches of the IL-2 production
pathway (155). The authors extend their findings to show that in Jurkat T cells , CD3-
and ZAP-70 phosphorylation are impaired by treatment with PD-L1.Fc conjugated beads.
These data identify a number of points in the IL-2 production pathway at which the
effects of PD- l signaling can be found.
There is more work that needs to be done to describe to relationship between the
PD- l negative costimulatory pathway and IL-2 production. Increasing our knowledge of
a signaling pathway that biochemically intervenes in the IL-2 production process has a
great deal of therapeutic potential. Finding ways to selectively activate the PD- l pathway
at specific times during an immune response or on specific populations of T cells may
enable the precise tailoring of an immune response, possibly leading to more advanced
transplantation protocols.
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Chapter 5-
Comprehensive Discussion
Induction and Maintenance of T cell anergy
Chapter 5 Introduction
The biochemical picture of T cell anergy is constantly being revised and
improved, and there are stil many details to be learned. Given the results shown here, it
is possible to develop a model assimilating what has previously been shown about the
signaling mechanisms in anergy, and these new findings. With each new study, it
becomes more evident that anergy depends on a complicated network of signals under
careful regulation. It is possible to divide the anergic phenotype into three major phases:
early induction, late induction, and maintenance/rechallenge (Figure 27). Within this
paradigm, it is possible to assign known anergy factors to each the phase, constructing a
progression of events that explain the phenotye of an anergic cell at each stage of the
process.
Proposed Phases of Anergy Induction and Maintenance
The TCR is able to signal by two pathways, one pathway transducing an
activation signal to the cell and the other establishing a hyporesponsive phenotype. It is
likely that the branching point at which these two diverge is reached a short time after
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Legend for Figure 27
Anergy is established by a progression of biochemical events, with different
phases being orchestrated by different types of factors. Shown here are the three
proposed phases of clonal anergy.
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TCR engagement, within 4- l6 hours (72). The activity of E3 ligases is probably most
crucial during this time, particularly that of GRAIL whose expression has been shown to
be up-regulated in anergic cells at 6 hours following ionomycin treatment, returning to
baseline by 18 hours (133). This timeframe can be thought of as the early induction
phase of anergy. It has been proposed that the expression of ubi quit in ligases early in the
induction of anergy serves to degrade key TCR-dependent signaling molecules such as
PLC-yl and PKC- , both of which are necessary for the production ofIL-2 (136).
The lack of initial IL-2 production after a signal through the TCR is the primary
determinant shunting T cells into anergy rather than productive stimulation, and it is
likely that it is the major role of E3 ligases in anergy is to prevent this initial IL-
production. A more extensive study of the kinetics of E3 ligase expression and the
specific timing of target degradation would be required to further flesh out this idea.
Egr-2 and PD-1 in different phases of anergy
We have shown that Egr- , a zinc-finger transcription factor, is important for
anergy induction, and that its expression is quickly decreased by the treatment of anergic
cells with IL-2. Despite the expression of Egr-2 at very early times in both anergic and
co stimulated T cell clones , it is likely that the actions of Egr-2 are most important at later
times , such as 48-72 hours following removal from the anergizing stimulus. During this
window, there is a marked distinction between Egr-2 expression levels in anergic and
costimulated cells; it is apparent that by this time the costimulated cells have proceeded
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to down-regulate Egr-2 as part of the process of progressing to cell cycle entry and
proliferation.
The process by which proliferating cells down-regulate Egr-2 is not known. One
possibility is that Egr-2 may be diluted as a consequence of cell division thus reducing
their levels to below some threshold level required for their activity. Another possibility
is that there is an active degradation process in place to override the anergic signaling
pathway in order to proceed to an activated status. It is most likely that the latter is the
case, given data showing that cells that receive a signal through the IL-2 receptor but do
not proliferate due to the presence of hydroxyurea can stil break anergy and are
responsive to antigenic stimulation following removal of the hydroxyurea (82).
The secondary and tertiary protein structure of Egr-2 reveal little other than its
ability to bind DNA with a C zinc-finger binding domain (180). This and numerous
other studies demonstrating the necessity of Egr-2 for expression of various proteins
suggest that its primary role in anergy is to up-regulate genes responsible for preventing
IL-2 production in anergic cells. This hypothesis is supported by the data shown here:
the knockdown of Egr-2 in anergic cells is effective in restoring proliferative capabilities
when Egr-2 siRNA is transfected into cells prior to the induction of anergy, but this
restoration does not occur when Egr-2 is depleted following the establishment of the
anergic phenotype.
Perhaps the best way to determine the targets of Egr-2 transactivation would be to
constitutively express Egr-2 in a population of T cells , stimulate the cells , and compare
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the transcriptome and proteome of the Egr-2-expressing cells with those of normally
anergized, fully stimulated, and untreated T cells.
The phase that includes the activity of those putative genes driven by Egr-2 can be
thought of as the maintenance phase of anergy. This is the phase in which the phenotype
of anergy actually manifests, resulting in the biochemical blocks that prevent IL-
production. Since a number of biochemical blocks in the TCR transduction pathways
have been observed in anergic cells, it is not unreasonable to think that anergy
maintenance is implemented by numerous factors ' acting in concert. The possibility
remains , however, that anergy is maintained by a single factor, whose functions can
prevent IL-2 production in anergic cells. The data presented here show that PD-
depletion during the maintenance phase of anergy results in a complete restoration of
antigenic responsiveness when compared with that of co stimulated cells, suggesting that
PD- l is capable of suppressing IL-2 production at least to a degree that lowers IL-2 levels
below the threshold required for entry into the cell cycle. It has been proposed that one
consequence of PD- l engagement in T cells is the suppression of IL-2 production
although the means by which it does this have not been definitively determined.
A summary of how these factors fit into the phases of anergy can be found in
Figure 28. If a small number of factors can be found whose actions are responsible for
preventing the proliferation of an anergic cell, the chances for effective therapeutic
intervention are greater than if an extensive and redundant biochemical network was in
place to suppress IL-2 production. Mapping out the active factors in each phase of
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Legend for Figure 28
The activities of factors discovered in our laboratory and others correspond to the
different phases of anergy.
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anergy offers the opportity to intervene prior to anergy induction, or to tr to reverse
anergy in a specific population of cells after anergy has been established. As there is
good evidence that anergy plays an important role in numerous instances of peripheral
tolerance, it may be possible to exploit anergy regulatory points to prevent an undesired
Immune response.
A comprehensive model of clonal anergy is shown in Figure 29. It is possible that
by refining our knowledge of the steps detailed in this diagram, we may be able to
identify means by which to harness the anergic phenotype in select populations of T cells.
A means of inducing a hypo-responsive state in allo-reactive T cells could lead to safer
less invasive ways to enable allo-transplantation while minimizing the risks and long-
term harm to patients.
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Legend for Figure 29
Early signaling events determine whether a T cell enters an anergIc state or
proceeds to productive clonal expansion. A. T cells that receive costimulation in addition
to a TCR signal do not express E3 ligases , the absence of which permits suffcient IL-
production to drive cell cycle progression. This leads to the down-regulation of Egr-
and PD- l leaving the cell subsequently capable of responding appropriately to antigenic
stimulation. B. The presence of E3 ligases early in an anergic cell leads to the
degradation of proteins crucial to IL-2 production, facilitating the full induction of
anergy, at least in part by the trans activating capabilities of Egr-2. It is likely that Egr-
directs the up-regulation of proteins whose activities are capable of rendering the cell
unresponsive to full antigenic stimulation. Whether PD- l expression is regulated directly
by Egr-2 or not, its high expression in anergic cells on day 5 after anergy induction is
able to prevent IL-2 production in anergic cells.
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Discussion of In Vivo Anergy PD- Expression
The data produced by the DO 11. 1 0 adoptive transfer experiments offer support to
the hypothesis that PD- l is up-regulated on tolerant populations of CD4+ T cells , but
there is a caveat to the data shown. In the absence of a control group showing a break in
peptide-induced tolerance (achievable by the use of any of a number of adjuvants) it is
difficult to emphatically claim that PD- l expression is specific to tolerized cells. Despite
the correlation seen here, it is possible that an immunized population of cells , having
received peptide in conjunction with adjuvant, could express PD- l at similar levels as the
peptide-tolerized cells, despite showing an ability to respond to antigen. The initial
attempts to include this control here resulted in an inability to prevent tolerance, despite
the inclusion of 25 f.g of lipopolysaccharide with the intravenously administered peptide.
This has been shown to be an effective way of breaking peptide-induced tolerance (112),
although in my hands, the cells treated with LPS and peptide were equally as
hyporesponsive as the peptide-tolerized cells , and did not show a significant decrease in
PD- l expression levels (data not shown). It is possible that increasing the amount of LPS
administered could result in a successful reversal of peptide-induced tolerance, or it may
be necessary to substitute another adjuvant for LPS to successfully reverse tolerance in
this case.
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Implications of PD-1 Expression in Costimulatory Blockade Protocols
It has not yet been clearly shown what peripheral tolerance mechanisms are
working when tolerance is induced with aCD 154 mAb and transfusions of donor
splenocytes, although there is good evidence that deletion of CD8+ cells (181) and
immune suppression by CD4 CD25+ T cells (182) are processes essential to allograft
tolerance. It is also possible that a population of donor-specific T cells is anergic
preventing them from respondIng to a graft. Identifying the antigen-specific population
of CD4+ cells to determine their anergic status is diffcult, although recently developed
protocols using CD4+ cells from TCR transgenic mice have the potential to enable this
type of experiment.
When total CD4+ cells are examined shortly after the administration of DST and
aCD154 mAb, it appears either that there is a block in PD- l expression or PD- l is being
actively down-regulated. It has not been shown that costimulation is required for PD-
expression; in fact, in the A.E7 T cell model PD- l is up-regulated strongly by TCR
engagement alone. The data shown here confirm data shown previously that aCD 154
down regulates PD- l expression in an allograft, even at 7 days post-transplantation (172),
although taken together these findings are diffcult to reconcile with those of studies
showing the ability of PD- l engagement to prolong allograft survival in conjunction with
other protocols (154). It is possible that the effects shown in total CD4+ cells in DST and
anti-CD 154-treated mice do not represent the subset ofCD4+ cells actually responding to
alloantigen, and that PD- l is being down-regulated on another population of cells.
Perhaps CD4 CD25+ cells actually need to expand in order to facilitate tolerance to an
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allograft, and are able to do this by down-regulating PD-l. Little has been published
about the surface expression of PD- l on CD4 CD25+ T cells , although one study has
identified PD- l on purified CD4 CD25+ populations (183). This study did not compare
PD- l levels on regulatory T cells to those of other cell populations, so the finding is not
entirely informative with regard to predicting what may be happening in the DST +
aCD154 protocol. If anergic cells are in fact employed in this tolerance protocol, it is
possible that they are important at times later than 7 days. There is suffcient evidence
that PD- l may playa significant role in peripheral tolerance, and it is very possible that
adding a means by which to activate PD- l negative regulatory pathways to avoid a
rejection response (perhaps both acute and chronic) could augment the graft survival
currently seen with established co stimulatory blockade protocols. Understanding the
means by which PD- l is able to negatively regulate alloimmune responses could provide
insight into new methods of therapeutic induction of graft tolerance, keeping in mind the
end goal of avoiding systemic immune suppression altogether.
Future Questions
The data presented in this thesis show two factors that are required for the
induction and maintenance of anergy. There are many questions left to answer. For
example , it wil be useful to know whether Egr-2 is directly up-regulating PD- , or if the
ability of Egr-2 to manage anergy induction is dependent on the up-regulation of other
gene products. Another interesting unkown is the mechanisms of how PD-
preventing anergic cells from proliferating, and more specifically how it is preventing IL-
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production. Preliminary experiments not shown here suggest that PD- is not
preventing ERK, Akt, NFKB , or PKC8 activation, thus it wil be necessary to examine
other important components of the IL-2 production pathways such as TCR , ZAP- , and
PLCy. Given that the cytoplasmic tail of PD- l is known to bind phosphatases, it is
possible that anergic cells express suffcient levels of PD- l to recruit high levels of
phosphatases to important signaling microdomains and thereby block the activation of
key signaling molecules. If this is the case, it may be possible to induce anergy
therapeutically by identifying agents that deactivate these same important signaling
molecules even in the absence of high levels ofPD-
Possible Roles for Anergy in Transplantation Tolerance
The role that anergy has in transplantation tolerance remains open to speculation.
It is tempting to contemplate a number of possibilities. Since CD8+ cells depend on IL-
produced by CD4+ cells , it is possible that rendering CD4+ cells anergic could prevent the
expansion of CD8+ cells by decreasing the amount of IL-2 help. Since CD8+ T cells are
vital to graft rejection, anergizing the CD4+ cells on which they depend could block this
aspect of the rejection process. It is also possible that B cell activation could be impaired
when CD4+ T cells are rendered anergic and unable to make suffcient cytokines to drive
B cell activation.
In addition to the implications of anergy in provision of IL-2 help, the process of
anergizing graft-specific CD4+ T cells could generate a subpopulation of regulatory T
cells that can prevent the activation of other CD4+ and CD8+ T cells. More specific
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markers for these populations need to be identified before good characterization of a
phenomenon like this would be possible. Anergic T cells may also playa role 
establishing a tolerizing environment. The Affymetrix mRNA profies generated early in
this project showed an increase in CCL- l production (data not shown), a chemokine
known to induce chemotaxis in CD4 CD25+ regulatory cells (184). If anergic T cells and
regulatory T cells are in fact distinct populations, it is possible they act in concert to
attenuate T cell responses at the site of a graft, with anergic cells migrating to a potential
inflammatory locus first and then establishing a CCL- l gradient to recruit regulatory T
cells. These are only a few possible ways that anergic cells could play an important role
in facilitating peripheral tolerance.
Final Conclusion
Furthering our understanding of the mechanisms of peripheral tolerance wil
enable the grafting of tissues and organs across HLA-incompatible environments , without
the use of systemic immunosuppression. It is possible that the induction of T cell anergy
is a means by which T cells can be trained not to mount an immune response against a
specific set of antigens. The knowledge that Egr-2 is a primary regulator of anergy
induction and PD- l is responsible for anergy maintenance could inform attempts to do
this with greater precision. Furher investigation into the downstream targets of Egr-
and the biochemical means by which PD- l negatively regulates T cell responses could
provide additional targets with the potential for therapeutic intervention. Given the
current state of research on negative co stimulation, and the data presented here, it is
154
possible that therapeutic agents tailored to impose tolerance by these pathways could
progress toward clinical applications in the near future.
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